<SEC-DOCUMENT>0001193125-26-294837.txt : 20260702
<SEC-HEADER>0001193125-26-294837.hdr.sgml : 20260702
<ACCEPTANCE-DATETIME>20260702165637
ACCESSION NUMBER:		0001193125-26-294837
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260702
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260702
DATE AS OF CHANGE:		20260702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ENANTA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001177648
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043205099
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35839
		FILM NUMBER:		261152573

	BUSINESS ADDRESS:	
		STREET 1:		4 KINGSBURY AVENUE
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617 607 0800

	MAIL ADDRESS:	
		STREET 1:		4 KINGSBURY AVENUE
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d123412d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enta="http://www.enanta.com/20260702" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2026-07-02_to_2026-07-02">ENANTA PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-277">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-07-02_to_2026-07-02">0001177648</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="enta-20260702.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-07-02_to_2026-07-02"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001177648</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-07-02</xbrli:startDate> <xbrli:endDate>2026-07-02</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-288">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt:datemonthdayyearen" id="ixv-289">July 2, 2026</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">ENANTA PHARMACEUTICALS, INC.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt-sec:stateprovnameen" id="ixv-290">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-291">001-35839</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-292">04-3205099</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-293">4 Kingsbury Avenue</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-294">Watertown</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt-sec:stateprovnameen" id="ixv-295">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-296">02472</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-297">(617)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-298">607-0800</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt-sec:boolballotbox" id="ixv-299">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt-sec:boolballotbox" id="ixv-300">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt-sec:boolballotbox" id="ixv-301">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt-sec:boolballotbox" id="ixv-302">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><br/>Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-303">Common Stock, par value $0.01 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-304">ENTA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt-sec:exchnameen" id="ixv-305">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-07-02_to_2026-07-02" format="ixt-sec:boolballotbox" id="ixv-306">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;1.01 Entry into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;2, 2026, Enanta Pharmaceuticals, Inc. (the &#8220;Corporation&#8221;) entered into an Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC, as sales agent (the &#8220;Agent&#8221;), pursuant to which the Corporation may offer and sell shares (the &#8220;Shares&#8221;) of its common stock, $0.01 par value per share (&#8220;Common Stock&#8221;), from time to time through the Agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Stock is being offered and sold pursuant to the Corporation&#8217;s previously filed and currently effective shelf registration statement on <span style="white-space:nowrap">Form&#160;S-3,</span> which was filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on February&#160;11, 2026 and declared effective on February&#160;20, 2026, containing a base prospectus (Registration Statement <span style="white-space:nowrap">No.&#160;333-293390).</span> The Corporation filed a prospectus supplement dated July&#160;2, 2026 with the Commission in connection with the offer and sale of the Shares. Pursuant to the prospectus supplement, the Corporation may offer and sell Shares having an aggregate offering price of up to $75,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of the Shares through the Agent, if any, will be made by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) under the Securities Act of 1933, as amended, including, without limitation, sales made directly on The Nasdaq Global Select Market or any other existing trading market for the Common Stock. The Agent will use commercially reasonable efforts to sell Common Stock from time to time, based upon instructions from the Corporation (including any price, time or size limits or other parameters or conditions the Corporation may impose). The Corporation has no obligation to sell any of the Shares under the Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporation will pay the Agent a commission of up to 3.0% of the gross sales price per share of Common Stock sold through the Agent under the Sales Agreement. The Corporation has also provided the Agent with customary indemnification rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of Common Stock pursuant to the Sales Agreement will terminate upon termination of the Sales Agreement in accordance with its terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion of Foley Hoag LLP regarding the Common Stock to be sold under the Sales Agreement is filed as Exhibit 5.1 hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d123412dex11.htm">Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup> dated July&#160;2, 2026, by and between Enanta Pharmaceuticals, Inc. and Jefferies LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d123412dex51.htm">Opinion of Foley Hoag LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d123412dex51.htm">Consent of Foley Hoag LLP (included in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: July&#160;2, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">ENANTA PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jay R. Luly, Ph.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jay R. Luly, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d123412dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPEN MARKET SALE AGREEMENT<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July&nbsp;2, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enanta Pharmaceuticals,
Inc., a Delaware corporation (the &#8220;<B>Company</B>&#8221;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the
&#8220;<B>Agent</B>&#8221;), shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;<B>Common Shares</B>&#8221;), on the terms set forth in this agreement (this &#8220;<B>Agreement</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. DEFINITIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Certain Definitions</U>. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the
following respective meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Affiliate</B>&#8221; of a Person means another Person that directly or indirectly, through one
or more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#8220;control&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common
control with&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Agency Period</B>&#8221; means the period commencing on the date of this Agreement and expiring on the earliest to occur of
(x)&nbsp;the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y)&nbsp;the date this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Commission</B>&#8221; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Exchange Act</B>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Floor Price</B>&#8221; means the minimum price set by the Company in the Issuance Notice below which the Agent
shall not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and
which in no event shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent&#8217;s sole discretion.
</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Open Market Sale Agreement&#8221; is a service mark of Jefferies LLC </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Issuance Amount</B>&#8221; means the aggregate Sales Price of the Shares to be
sold by the Agent pursuant to any Issuance Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Issuance Notice</B>&#8221; means a written notice delivered to the Agent by
the Company in accordance with this Agreement in the form attached hereto as Exhibit A that is executed by its Chief Executive Officer, President, Chief Financial Officer, Principal Financial Officer or Chief Legal Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Issuance Notice Date</B>&#8221; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to
<U>Section</U><U></U><U>&nbsp;3(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Issuance Price</B>&#8221; means the Sales Price less the Selling Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Maximum Program Amount</B>&#8221; means Common Shares with an aggregate Sales Price of the lesser of (a)&nbsp;the number or dollar
amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b)&nbsp;the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise,
conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (including General Instruction I.B.6 thereof, if applicable), or (d)&nbsp;the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Person</B>&#8221; means an individual or a corporation, partnership, limited liability company, trust, incorporated or
unincorporated association, joint venture, joint stock company, governmental authority or other entity of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Principal
Market</B>&#8221; means the Nasdaq Global Select Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Rule 462(b) Registration Statement</B>&#8221; means any registration statement filed by the Company pursuant to Rule 462(b) under
the Securities Act in connection with the offer and sale of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Sales Price</B>&#8221; means the actual sale execution
price of each Share placed by the Agent pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Securities Act</B>&#8221; means the Securities Act of 1933,
as amended, and the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Selling Commission</B>&#8221; means up to three percent
(3.0%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Settlement Date</B>&#8221; means the first business day following each Trading Day
during the period set forth in the Issuance Notice on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance
Price received on such sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Shares</B>&#8221; shall mean the Company&#8217;s Common Shares issued or issuable pursuant to
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Trading Day</B>&#8221; means any day on which the Principal Market is open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to, and agrees with, the Agent that as of (1)&nbsp;the date of this Agreement, (2)&nbsp;each Issuance
Notice Date, (3)&nbsp;each Settlement Date, (4)&nbsp;each Triggering Event Date (as defined below) and (5)&nbsp;each Time of Sale (as defined below) (each of the times referenced above is referred to herein as a &#8220;<B>Representation
Date</B>&#8221;), except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement</U>. The Company has filed with the Commission a shelf registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-293390)</FONT> that contains a base prospectus. Such registration statement registers the issuance and sale by the Company of the Shares under the Securities
Act. The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Shares. Except where the context
otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules thereto and all documents
incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act as from time to time amended or supplemented, is herein referred to as the
&#8220;<B>Registration Statement,</B>&#8221; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a
particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, in each case, as from time to
time amended or supplemented, is referred to herein as the &#8220;<B>Prospectus,</B>&#8221; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares that is not required to
be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#8220;<B>Prospectus</B>&#8221; shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use. The Registration
Statement at the time it originally became effective is herein called the &#8220;<B>Original Registration Statement.</B>&#8221; As used in this Agreement, the terms &#8220;amendment&#8221; or &#8220;supplement&#8221; when applied to the Registration
Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information
which is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and
schedules and other information which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any
specified date; and all references in this Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or
is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time the Original Registration Statement became effective and at the time the Company&#8217;s most recent annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> was filed with the Commission, if later, the Company met the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. During the Agency Period, each
time the Company files an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> the Company will meet the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Compliance with Registration Requirements</U>. The Original Registration Statement and any Rule 462(b) Registration Statement have been
declared or deemed effective by the Commission under the Securities Act. The Company has complied to the Commission&#8217;s satisfaction with all requests of the Commission for additional or supplemental information. No stop order suspending the
effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus when filed complied or will comply in all material respects with the Securities Act and, if filed with the
Commission through its Electronic Data Gathering, Analysis and Retrieval system (&#8220;<B>EDGAR</B>&#8221;) (except as may be permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> under the Securities Act), was identical to the copy
thereof delivered to the Agent for use in connection with the issuance and sale of the Shares. Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto, at the time it became or becomes
effective and at each Representation Date, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered together (collectively, the &#8220;<B>Time of Sale
Information</B>&#8221;) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus,
as amended or supplemented, as of its date and at each Representation Date, did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule 462(b)
Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the
Agent expressly for use therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in <U>Section</U><U></U><U>&nbsp;6</U> below. There are no contracts or other
documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated hereby
meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Ineligible Issuer Status</U>. The Company is not an &#8220;ineligible issuer&#8221;
in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed
with the Commission in accordance with the requirements of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of
or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such
Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the
information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein. Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to the Agent before first
use, the Company has not prepared, used or referred to, and will not, without the Agent&#8217;s prior consent, such consent not to be unreasonably withheld, conditioned or delayed, prepare, use or refer to, any Free Writing Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Incorporated Documents</U>. The documents incorporated by reference in the Registration Statement and the Prospectus, when they were
filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement and the Prospectus, when such documents are filed with the
Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Financial Statements</U>. The financial statements (including the related
notes thereto) of the Company and its consolidated subsidiary included or incorporated by reference in the Registration Statement and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the
Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiary as of the dates indicated and the results of their operations and the changes in their cash flows for the
periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;<B>GAAP</B>&#8221;) in the United States applied on a consistent basis throughout the periods covered thereby, and
any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial information included or incorporated by
reference in the Registration Statement and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiary and presents fairly in all material respects the information shown thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>No Material Adverse Change</U>. Since the date of the most recent financial
statements of the Company included or incorporated by reference in the Registration Statement and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of Common Shares upon exercise of stock options
described as outstanding in, and the grant of options and the grant, vesting and settlement of awards under existing equity incentive plans described in, the Registration Statement and the Prospectus), short-term debt or long-term debt of the
Company or its subsidiary, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development involving a prospective material
adverse change, in or affecting the business, properties, management, financial position, stockholders&#8217; equity, results of operations or prospects of the Company and its subsidiary taken as a whole; (ii)&nbsp;neither the Company nor its
subsidiary has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiary taken as a whole or incurred any liability or obligation, direct or contingent, that is
material to the Company and its subsidiary taken as a whole; and (iii)&nbsp;neither the Company nor its subsidiary has sustained any loss or interference with its business that is material to the Company and its subsidiary taken as a whole and that
is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each
case as otherwise disclosed in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Organization and Good Standing</U>. The Company and
its subsidiary have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their
respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they
are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties,
management, financial position, stockholders&#8217; equity, results of operations or prospects of the Company and its subsidiary taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#8220;<B>Material
Adverse Effect</B>&#8221;). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than as disclosed in Exhibit 21.1 to the Company&#8217;s most recent Annual Report on Form 10-K. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Capitalization</U>. The Company has an authorized capitalization as set forth in the Registration Statement and the Prospectus under the
heading &#8220;<B>Description of Capital Stock</B>&#8221;; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and
are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights; except as described in or expressly contemplated by the Registration Statement and the Prospectus, there are no outstanding rights (including, without
limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or its subsidiary, or
any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or
options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each
subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly or indirectly by the Company, free and clear
of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Stock Options</U>. With respect to the stock options (the &#8220;<B>Stock
Options</B>&#8221;) granted pursuant to the stock-based compensation plans of the Company and its subsidiary (the &#8220;<B>Company Stock Plans</B>&#8221;), except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, (i)&nbsp;each Stock Option intended to qualify as an &#8220;incentive stock option&#8221; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder
(the &#8220;<B>Code</B>&#8221;) so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as
applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such
grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements,
including the rules of the Principal Market and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of
the Company and disclosed in the Company&#8217;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company
of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or its subsidiary or their results of operations or prospects.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Due Authorization</U>. The Company has full right, power and authority to execute and deliver this Agreement and to perform its
obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>This Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>The Shares</U>. The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and
delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement and the Prospectus; and the issuance of the Shares is not
subject to any preemptive or similar rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Description of this Agreement</U>. This Agreement conforms in all material respects to
the description thereof contained in the Registration Statement and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>No Violation or Default</U>. Neither the Company nor its subsidiary is (i)&nbsp;in
violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or its subsidiary is a party or by which the Company or its
subsidiary is bound or to which any property or asset of the Company or its subsidiary is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory
authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the
consummation of the transactions contemplated by this Agreement and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination,
modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or its subsidiary pursuant to, any indenture, mortgage, deed of trust, loan agreement or
other agreement or instrument to which the Company or its subsidiary is a party or by which the Company or its subsidiary is bound or to which any property, right or asset of the Company or its subsidiary is subject, (ii)&nbsp;result in any
violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or its subsidiary or (iii)&nbsp;result in the violation of any law or statute or any judgment, order,
rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>No Consents Required</U>. No consent,
approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale
of the Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may
be required by the Financial Industry Regulatory Authority, Inc. (&#8220;<B>FINRA</B>&#8221;), the Principal Market and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Legal Proceedings</U>. Except as described in the Registration Statement and the Prospectus, there are no legal, governmental or
regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#8220;<B>Actions</B>&#8221;) pending to which the Company or its subsidiary is or may be a party or to which any property of the Company or its
subsidiary is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or its subsidiary, would reasonably be expected to have a Material Adverse Effect; and no such Actions are threatened or, to the
knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement
or the Prospectus that are not so described in the Registration Statement and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the
Registration Statement or described in the Registration Statement or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Independent Accountants</U>. PricewaterhouseCoopers LLP, who has expressed its
opinion with respect to certain financial statements of the Company and its subsidiary, is an independent registered public accounting firm with respect to the Company and its subsidiary within the applicable rules and regulations adopted by the
Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Title to Real
and Personal Property</U>. The Company and its subsidiary have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the
Company and its subsidiary, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by
the Company and its subsidiary or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Intellectual Property</U>. (i)&nbsp;To the knowledge of the Company, the Company and its subsidiary own or have the right to use all
patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and copyrightable works,
<FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, systems, procedures, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights (collectively,
&#8220;<B>Intellectual Property</B>&#8221;) used in the conduct of their respective businesses as currently conducted or as currently proposed to be conducted, except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect; (ii)&nbsp;the Company&#8217;s and its subsidiary&#8217;s conduct of their respective businesses does not, to the knowledge of the Company, infringe, misappropriate or otherwise violate any Intellectual Property of any
person; and (iii)&nbsp;the Company and its subsidiary have not received any notice of any claim relating to the Intellectual Property rights of others that would, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. The Intellectual Property of the Company and its subsidiary has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company&#8217;s knowledge, except as disclosed in the
Registration Statement and the Prospectus: (i)&nbsp;there are no third parties who have rights to any Intellectual Property of the Company and its subsidiary, except for customary reversionary rights of third-party licensors with respect to
Intellectual Property that is disclosed in the Registration Statement and the Prospectus as licensed to the Company or its subsidiary; (ii)&nbsp;there is no infringement, misappropriation, or other violation by third parties of any Intellectual
Property of the Company and its subsidiary; (iii)&nbsp;there are no material defects of form in the preparation or filing of any of the patents or patent applications included in the Intellectual Property of the Company and its subsidiary;
(iv)&nbsp;the Company and its subsidiary have taken commercially reasonable steps to protect, maintain and safeguard its Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment
agreements and invention assignments with their employees; (v)&nbsp;no employee of the Company and its subsidiary is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation
relates to such employee&#8217;s employment with the Company or one or more of its subsidiary; (vi)&nbsp;the duty of candor and good </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property of the Company
and its subsidiary has been complied with; and in all foreign offices having similar requirements, all such requirements have been complied with; and (vii)&nbsp;none of the Intellectual Property of the Company and its subsidiary or technology
(including information technology and outsourced arrangements) employed by the Company or its subsidiary has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its
subsidiary or, to the knowledge of the Company, any of their respective officers, directors or employees or otherwise in violation of the rights of any persons. Except as disclosed in the Registration Statement and the Prospectus, and except with
respect to the prosecution of patent applications within the Intellectual Property occurring before national and regional patent offices in the normal course of business, there is no pending or, to the Company&#8217;s knowledge, threatened action,
suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#8217;s and its subsidiary&#8217;s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action,
suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property of the Company and its subsidiary; or (C)&nbsp;asserting that the Company or its subsidiary infringes or otherwise violates, or would,
upon the commercialization of any product or service described in the Registration Statement or the Prospectus as under development, infringe or violate, any intellectual property rights of others. To the knowledge of the Company, the Company and
its subsidiary have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, in all material respects, and all such agreements are, to the knowledge of the Company, in full
force and effect. The product candidates described in the Registration Statement and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents or patent applications owned by, or
exclusively licensed to, the Company or any subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>No Undisclosed Relationships</U>. No relationship, direct or indirect,
exists between or among the Company or its subsidiary, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiary, on the other, that is required by the Securities Act
to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Investment
Company Act</U>. The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement and the Prospectus, will not be required to register as an
&#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder
(collectively, the &#8220;<B>Investment Company Act</B>&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Taxes</U>. Except as would not reasonably be expected to have a
Material Adverse Effect, the Company and its subsidiary have filed all federal, state, local and foreign tax returns required to be filed through the date hereof and have paid all taxes required to be paid whether or not reported thereon; and except
as otherwise disclosed in each of the Registration Statement and the Prospectus and as would not reasonably be expected to have a Material Adverse Effect, there is no tax deficiency that has been, or could reasonably be expected to be, asserted
against the Company or its subsidiary or any of their respective properties or assets. There are no outstanding agreements or waivers extending the statutory period of limitation applicable to any federal, state, local or foreign tax return for any
period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Licenses and Permits</U>. The Company and its subsidiary possess all licenses, <FONT
STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits, registrations, applications, approvals, clearances, exemptions, franchises, consents and other authorizations issued by, and have made all declarations and filings with, the
appropriate federal, state, local or foreign governmental or regulatory authorities, including the FDA, that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each
of the Registration Statement and the Prospectus (collectively, &#8220;<B>Licenses</B>&#8221;), except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect; and except as described in each of the Registration Statement and the Prospectus, neither the Company nor its subsidiary has received notice that any governmental or regulatory authority, including the FDA, has taken, is taking, or intends
to take action to limit, suspend, modify or revoke any License and has no knowledge that any action is being considered; and neither the Company nor its subsidiary has any reason to believe that any License will not be renewed in the ordinary
course, in each case except where such notice or <FONT STYLE="white-space:nowrap">non-renewal</FONT> would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>FDA Compliance</U>. The Company and its subsidiary: (A)&nbsp;are and at all times have been in material compliance with the Federal
Food, Drug and Cosmetic Act (&#8220;<B>FDCA</B>&#8221;), and all statutes, rules or regulations of the U.S. Food and Drug Administration (&#8220;<B>FDA</B>&#8221;) and of other comparable governmental or regulatory authorities applicable to the
ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by or on
behalf of the Company (&#8220;<B>Applicable Laws</B>&#8221;); (B) have not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any governmental or regulatory
authority alleging or asserting noncompliance with any Applicable Laws or any Licenses, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (C)&nbsp;possess all Licenses and such Licenses
are valid and in full force and effect and the Company and its subsidiary are not in violation of any term of any such Licenses, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;
(D)&nbsp;have not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any governmental or regulatory authority or third party alleging that any product
operation or activity is in violation of any Applicable Laws or Licenses and have no knowledge that the FDA or any governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit,
investigation or proceeding; and (E)&nbsp;have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Licenses
and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent
submission). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Tests and Preclinical and Clinical Trials</U>. (A)&nbsp;The studies, tests and preclinical and clinical trials
conducted by or, to the Company&#8217;s knowledge, on behalf of the Company that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still ongoing, are, and with respect to those
studies not conducted by the Company are to the Company&#8217;s knowledge, being conducted in all material respects in accordance with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protocols submitted to the FDA or any comparable foreign governmental or regulatory authority exercising comparable authority, procedures and controls pursuant to, where applicable, accepted
professional scientific standards, and all Licenses and Applicable Laws and regulations, and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; (B)&nbsp;the descriptions of the results of
such studies, tests and trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects; (C)&nbsp;the Company is not aware of any studies, tests or trials, the results of which the Company
believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described and the clinical state of development;
and (D)&nbsp;the Company has not received any written notices or correspondence from the FDA or any governmental or regulatory authority requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or
on behalf of the Company that are described or referred to in the Registration Statement or the Prospectus, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Compliance with Health Care Laws</U>. The Company and its subsidiary are, and at all times have been, in material compliance with all
Health Care Laws. For purposes of this Agreement, &#8220;<B>Health Care Laws</B>&#8221; means: (i)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute
(42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal False Statements Law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286, 287 and 1349, the health care fraud criminal provisions under HIPAA (as defined below), the civil monetary penalties law (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusions law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7h),</FONT> and the laws governing U.S. government funded or sponsored healthcare programs; (ii)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the
regulation of the Company or its subsidiary, and (iii)&nbsp;the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company, nor its subsidiary, nor, to the knowledge of the Company, any of
its respective officers, directors, employees or agents, have engaged or are engaging in activities which are cause for liability under any applicable Health Care Laws, including the FDCA. Neither the Company nor its subsidiary has received written
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other material action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or
activity is in material violation of any Health Care Laws nor, to the Company&#8217;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other material action threatened. The Company and its
subsidiary have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor its
subsidiary is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Neither the Company, nor its subsidiary, nor
any of its respective officers, directors, employees, clinical investigators, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the
Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>No Labor Disputes</U>. No labor disturbance by or dispute with employees of the
Company or its subsidiary exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of its or its subsidiary&#8217;s
principal suppliers, contractors or customers, except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor its subsidiary has received any notice of cancellation or termination with respect to any collective
bargaining agreement to which it is a party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Certain Environmental Matters</U>. (i)&nbsp;The Company and its subsidiary
(x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable
requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#8220;<B>Environmental Laws</B>&#8221;); (y) have
received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;have not
received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic
substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; and (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of
or relating to the Company or its subsidiary, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except
as described in the Prospectus, (y)&nbsp;the Company and its subsidiary are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic
substances or wastes, pollutants or contaminants, that could reasonably be expected to have a Material Adverse Effect on the capital expenditures, earnings or competitive position of the Company and its subsidiary, and (z)&nbsp;neither the Company
nor its subsidiary anticipates capital expenditures relating to any Environmental Laws except as would not reasonably be expected to have a Material Adverse Effect. There is no pending or, to the Company&#8217;s knowledge, threatened administrative,
regulatory or judicial action, claim or notice of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or its subsidiary, except in each case which, individually or in the aggregate, would
not reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>Compliance with ERISA</U>. (i)&nbsp;Each employee benefit plan,
within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#8220;<B>ERISA</B>&#8221;), for which the Company or any member of its &#8220;<B>Controlled Group</B>&#8221; (defined as any entity, whether
or not incorporated, that is under common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of
the Code) would have any liability (each, a &#8220;<B>Plan</B>&#8221;) has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited
transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that
is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of
Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#8220;at risk status&#8221; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a
&#8220;multiemployer plan&#8221; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#8220;endangered status&#8221; or &#8220;critical status&#8221; (within the meaning of Sections 304 and 305 of ERISA); (v) the fair market value of the
assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#8220;reportable event&#8221; (within the meaning of Section&nbsp;4043(c) of ERISA and the
regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or by
failure to act, which would cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions
to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#8220;multiemployer plan&#8221; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and
(ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the
current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#8217;s and its Controlled Group affiliates&#8217; most recently completed fiscal year; or (B)&nbsp;a material
increase in the Company and its subsidiary&#8217;s &#8220;accumulated post-retirement benefit obligations&#8221; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of
such obligations in the Company and its subsidiary&#8217;s most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Disclosure Controls</U>. The Company and its subsidiary maintain an
effective system of &#8220;disclosure controls and procedures&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to
ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms,
including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiary have
carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>Accounting Controls</U>. The Company and its subsidiary maintain systems of
&#8220;internal control over financial reporting&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the
supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP. The Company and its subsidiary maintain internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#8217;s
general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in
accordance with management&#8217;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in
accordance with the Commission&#8217;s rules and guidelines applicable thereto. Based on the Company&#8217;s most recent evaluation of its internal controls over financial reporting pursuant to Rule <FONT STYLE="white-space:nowrap">13a-15(c)</FONT>
of the Exchange Act, there are no material weaknesses in the Company&#8217;s internal controls. The Company&#8217;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies
and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report
financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>eXtensible Business Reporting Language</U>. The interactive data in eXtensible Business Reporting Language included or incorporated by
reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <U>Insurance</U>. The Company and its subsidiary have insurance covering their respective properties, operations, personnel and
businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably considers are adequate to protect the Company and its subsidiary and their respective
businesses; and neither the Company nor its subsidiary has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or
(ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at a cost that would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Cybersecurity; Data Protection</U>. The Company and its subsidiary&#8217;s information technology assets and equipment, computers,
systems, networks, hardware, software, websites, applications, databases, and any third party services (collectively, &#8220;<B>IT Systems</B>&#8221;) are (i)&nbsp;adequate for, and operate and perform in all material respects as required in
connection with the operation of the business of the Company and its subsidiary as currently conducted, and (ii)&nbsp;to the knowledge of the Company, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants. The Company and its subsidiary have implemented and at all times maintained and complied in all material respects with commercially reasonable controls, policies, procedures, and safeguards to maintain and protect the confidentiality,
integrity, availability, privacy and security of all Personal Data (defined below) and all other sensitive, confidential or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulated data maintained by or on behalf of the Company (collectively, &#8220;<B>Confidential Data</B>&#8221;) used in connection with their businesses, and there have been no material breaches,
violations, outages or unauthorized uses of or accesses to IT Systems or Confidential Data, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review
or investigations relating to the same. The Company and its subsidiary are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or
regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Confidential Data and to the protection of such IT Systems and Confidential Data from unauthorized use, access,
misappropriation or modification. The Company and its subsidiary comply, and have at all times complied, in all material respects, with all applicable laws, statutes, rule, directives, industry standards and regulations concerning the protection,
collection, use, disclosure, transfer, storage, disposal, privacy, confidentiality, integrity, security, or other processing of Personal Data (including without limitation, in each case as applicable, the Health Insurance Portability and
Accountability Act of 1996 (&#8220;<B>HIPAA</B>&#8221;) as amended by the Health Information Technology for Economic and Clinical Health Act (the &#8220;<B>HITECH Act</B>&#8221;); the European Union General Data Protection Regulation
(&#8220;GDPR&#8221;) (EU 2016/679); the UK GDPR; Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221; 90 Fed. Reg. 1636 (Jan. 8, 2025) codified at 28 C.F.R. &#167; 202, including any
amendments thereto and guidance issued thereunder (together, the &#8220;<B>U.S. Data Security Program</B>&#8221;); and the California Consumer Privacy Act (&#8220;<B>CCPA</B>&#8221;) (collectively, the &#8220;<B>Privacy Laws</B>&#8221;)). The
Company has made all required disclosures to and obtained all necessary consents from individuals, users or customers required under applicable Privacy Laws for the Company&#8217;s collection, use, disclosure, transfer, and other processing of
Personal Data, and has complied with all such disclosures and consents in all material respects. None of such disclosures made or contained in any policies or notices have been inaccurate or in violation of any Privacy Laws in any material respect.
&#8220;<B>Personal Data</B>&#8221; means (i)&nbsp;any information which would qualify as &#8220;personally identifying information&#8221;, &#8220;personal information&#8221;, &#8220;personally identifying information&#8221;, or similar term as
defined by Privacy Laws; or (ii)&nbsp;any other piece of information that relates to an identified or identifiable natural person, or that is reasonably capable of being used to identify, contact, or precisely locate a natural person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>No Unlawful Payments</U>. Neither the Company nor its subsidiary nor any director, officer or employee of the Company or its subsidiary
nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or its subsidiary has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee,
including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for
political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials
in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The
Company and its subsidiary have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Compliance with Anti-Money Laundering Laws</U>. The operations of the Company and its subsidiary are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where
the Company or its subsidiary conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#8220;<B>Anti-Money
Laundering Laws</B>&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or its subsidiary with respect to the Anti-Money Laundering Laws is pending or, to
the knowledge of the Company, threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <U>No Conflicts with Sanctions Laws</U>. Neither the Company nor its subsidiary, directors,
officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or its subsidiary is currently the subject or the target of any sanctions administered or enforced
by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;<B>OFAC</B>&#8221;) or the U.S. Department of State and including, without limitation, the designation as a
&#8220;specially designated national&#8221; or &#8220;blocked person&#8221;), the United Nations Security Council (&#8220;<B>UNSC</B>&#8221;), the European Union, His Majesty&#8217;s Treasury (&#8220;<B>HMT</B>&#8221;) or other relevant sanctions
authority (collectively, &#8220;<B>Sanctions</B>&#8221;), nor is the Company or its subsidiary located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the Crimea Region of
Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#8217;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#8217;s Republic, Cuba, Iran, North Korea and Syria (each, a &#8220;<B>Sanctioned
Country</B>&#8221;); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or
entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any
Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since April&nbsp;24,
2019, the Company and its subsidiary have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or
with any Sanctioned Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>Outbound Investment Security Program</U>. Neither the Company nor its subsidiary is a &#8220;covered
foreign person&#8221;, as that term is defined in 31 C.F.R. &#167; 850.209. Neither the Company nor its subsidiary currently engages, or has plans to engage, directly or indirectly, in a &#8220;covered activity&#8221;, as that term is defined in in
31 C.F.R. &#167; 850.208 (&#8220;<B>Covered Activity</B>&#8221;). The Company does not have any joint ventures that engage in or plan to engage in any Covered Activity. The Company also does not, directly or indirectly, hold a board seat on, have a
voting or equity interest in, or have any contractual power to direct or cause the direction of the management or policies of any person or persons that engages or plans to engage in any Covered Activity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>No Restrictions on Subsidiaries</U>. No subsidiary of the Company is currently
prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#8217;s capital stock or similar
ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#8217;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <U>No Broker&#8217;s Fees</U>. Neither the Company nor its subsidiary is a party to any contract, agreement or understanding with any
person (other than this Agreement) that would give rise to a valid claim against either of them or the Agent for a brokerage commission, finder&#8217;s fee or like payment in connection with the offering and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <U>No Registration Rights</U>. No person has the right to require the Company or its subsidiary to register any securities for sale under
the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)
<U>No Stabilization</U>. Neither the Company nor its subsidiary or affiliates has taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the
Shares, whether to facilitate the sale or resale of the Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <U>Margin Rules</U>. Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as
described in each of the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <U>Forward-Looking Statements</U>. No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and
Section&nbsp;21E of the Exchange Act) included or incorporated by reference in either of the Registration Statement or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith and is
accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statements. No such statement was made with the knowledge of an executive officer or
director of the Company that it was false and misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <U>Statistical and Market Data</U>. Nothing has come to the attention of
the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement and the Prospectus is not based on or derived from sources that are reliable
and accurate in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <U>Sarbanes-Oxley Act</U>. There is and has been no failure on the part of the Company or any
of the Company&#8217;s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith,
including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <U>Status under the Securities Act</U>. At the time of filing the Registration
Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date
hereof, the Company was not and is not an &#8220;ineligible issuer&#8221;, as defined in Rule 405 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <U>No
Ratings</U>. There are no debt securities, convertible securities or preferred stock issued or guaranteed by the Company or its subsidiary that are rated by a &#8220;nationally recognized statistical rating organization&#8221;, as such term is
defined in Section&nbsp;3(a)(62) under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <U>No Outstanding Loans or Other Extensions of Credit</U>. The Company does
not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of
the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) <U>Other Underwriting Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for
any other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;at-the-market&#8221;</FONT></FONT> or continuous equity transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) <U>FINRA Matters</U>. All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers
and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete, correct and compliant in all material respects with FINRA&#8217;s
rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct in all material respects. The Company meets the definition of the term &#8220;experienced
issuer&#8221; specified in FINRA Rule 5110(j)(6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer or representative of the Company or its
subsidiary and delivered to the Agent or counsel for the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(p)</U>
hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. ISSUANCE AND SALE OF COMMON SHARES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Sale of Securities</U>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales
Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Mechanics of Issuances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Issuance Notice</U>. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which
the conditions set forth in <U>Section</U><U></U><U>&nbsp;5(a)</U> and <U>Section</U><U></U><U>&nbsp;5(b)</U> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance
Notice; provided, however, that (A)&nbsp;in no event may the Company deliver an Issuance Notice to the extent that (I)&nbsp;the sum of (x)&nbsp;the aggregate Sales Price of the requested Issuance Amount, plus (y)&nbsp;the aggregate Sales Price of
all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B)&nbsp;prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall
have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by email to the persons set forth in Schedule A hereto and confirmed by the Company by telephone (including a voicemail message
to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Agent Efforts</U>. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice,
the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information
specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may
modify an Issuance Notice at any time provided they both agree in writing to any such modification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Method of Offer and Sale</U>.
The Shares may be offered and sold (A)&nbsp;in negotiated transactions with the consent of the Company or (B)&nbsp;by any other method permitted by law deemed to be an &#8220;<B>at the market offering</B>&#8221; as defined in Rule 415(a)(4) under
the Securities Act, including block transactions, sales made directly on the Principal Market or sales made into any other existing trading market of the Common Shares. Nothing in this Agreement shall be deemed to require either party to agree to
the method of offer and sale specified in the preceding sentence, and (except as specified in clause (A)&nbsp;above) the method of placement of any Shares by the Agent shall be at the Agent&#8217;s discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Confirmation to the Company</U>. If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no
later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of such Shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the
Company in respect thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Settlement</U>. Each issuance of Shares will be settled on the applicable Settlement Date for such
issuance of Shares and, subject to the provisions of <U>Section</U><U></U><U>&nbsp;5</U>, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent
or its designee&#8217;s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares,
which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account
designated by the Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a &#8220;<B>Time of Sale</B>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Suspension or Termination of Sales</U>. Consistent with standard market settlement
practices, the Company or the Agent may, upon notice to the other party hereto in writing (including by email) or by telephone (confirmed promptly by verifiable email), suspend any sale of Shares, and the period set forth in an Issuance Notice shall
immediately terminate; provided, however, that (A)&nbsp;such suspension and termination shall not affect or impair either party&#8217;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice; (B)&nbsp;if
the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with <U>Section</U><U></U><U>&nbsp;3(b)(v)</U> with respect to such Shares; and (C)&nbsp;if the
Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable and
documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares
from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v)&nbsp;above, and may use the Shares to settle or close out such borrowings. The Company agrees that no such notice shall be
effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(</U><U>i</U><U>)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>No Guarantee of Placement, Etc</U>. The Company acknowledges and agrees that (A)&nbsp;there can be no assurance that the Agent will be
successful in placing Shares; (B)&nbsp;the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares; and (C)&nbsp;the Agent shall be under no obligation to purchase Shares on a principal basis
pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Material <FONT
STYLE="white-space:nowrap">Non-Public</FONT> Information</U>. Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be
obligated to place any Shares, during any period in which the Company is in possession of material <FONT STYLE="white-space:nowrap">non-public</FONT> information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Fees</U>. As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling
Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(vi)</U>) by the Agent deducting the Selling Commission from the applicable Issuance Amount. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses</U>. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations
hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs); (ii) all fees and expenses of
the registrar and transfer agent of the Shares; (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares; (iv)&nbsp;all fees and expenses </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company&#8217;s counsel, independent public or certified public accountants and other advisors; (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing,
filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below) prepared by or on behalf of,
used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement; (vi)&nbsp;all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering
(or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing
and printing a &#8220;<B>Blue Sky Survey</B>&#8221; or memorandum and a &#8220;Canadian wrapper&#8221;, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions; (vii)&nbsp;the reasonable
and documented fees and disbursements of the Agent&#8217;s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#8217;s participation in the offering and
distribution of the Shares; (viii)&nbsp;the filing fees incident to FINRA review, if any; (ix)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing
of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any
consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the
cost of any aircraft chartered in connection with the road show; and (x)&nbsp;the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent&#8217;s counsel pursuant to subsections (vi)&nbsp;and
(vii) above shall not exceed (A)&nbsp;$75,000 in connection with the execution of this Agreement; (B)&nbsp;$25,000 in connection with each Triggering Event Date (as defined below) involving the filing of a Form
<FONT STYLE="white-space:nowrap">10-K</FONT> on which the Company is required to provide a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o) </U>and (C)&nbsp;$15,000 in connection with each other Triggering Event Date (as defined below) on
which the Company is required to provide a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4. ADDITIONAL
COVENANTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere
in this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exchange Act Compliance</U>. During the Agency Period, the Company shall (i)&nbsp;file, on a timely basis, with
the Commission all reports and documents required to be filed under Section&nbsp;13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act; and (ii)&nbsp;either (A) include in its quarterly reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and its annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> a summary detailing, for the relevant reporting period, (1)&nbsp;the number of Shares sold through the Agent pursuant to
this Agreement and (2)&nbsp;the net proceeds received by the Company from such sales or (B)&nbsp;prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#8220;<B>Interim
Prospectus Supplement</B>&#8221;), such summary information and, at least once a quarter and subject to this <U>Section </U><U>4</U>, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time
periods required by Rule 424(b) and Rule 430B under the Securities Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Securities Act Compliance</U>. After the date of this Agreement, the Company shall
promptly advise the Agent in writing (i)&nbsp;of the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;of the time and date of any filing of any post-effective amendment to the
Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or any Free Writing Prospectus; (iii)&nbsp;of the time and date that any post-effective amendment to the Registration Statement or any
Rule 462(b) Registration Statement becomes effective and (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration
Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common
Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at
any time, the Company will use its best efforts to obtain the lifting of such order as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities
Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition exist as a
result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including
the Securities Act, the Company agrees (subject to <U>Section</U><U></U><U>&nbsp;4(d)</U> and <U>Section</U><U></U><U>&nbsp;4(f)</U>) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or
supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances when the Prospectus is delivered to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act. Neither the Agent&#8217;s consent to, or
delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#8217;s obligations under <U>Section</U><U></U><U>&nbsp;4(d)</U> and <U>Section</U><U></U><U>&nbsp;4(f)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Agent</U><U>&#8217;</U><U>s Review of Proposed Amendments and Supplements</U>. Prior to amending or supplementing the Registration
Statement (including any Rule 462(b) Registration Statement) or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable
amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent&#8217;s prior consent, such
consent not to be unreasonably withheld, conditioned or delayed, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Use of Free Writing Prospectus</U>. Neither the Company nor the Agent has prepared,
used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#8217;s prior written consent, any &#8220;written communication&#8221; that constitutes a &#8220;free writing prospectus&#8221; as such terms are
defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#8220;<B>Free Writing Prospectus</B>&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Free Writing Prospectuses</U>. The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time
of filing or use thereof, a copy of each proposed Free Writing Prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed
Free Writing Prospectus or any amendment or supplement thereto without the Agent&#8217;s consent, such consent not to be unreasonably withheld, conditioned or delayed. The Company shall furnish to the Agent, without charge, as many copies of any
Free Writing Prospectus prepared by or on behalf of, or used by the Company, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be
delivered in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any Free Writing Prospectus prepared by or on
behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such Free Writing Prospectus to eliminate or
correct such conflict or so that the statements in such Free Writing Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be; provided, however, that prior to amending or supplementing any such Free Writing Prospectus, the Company shall furnish to the Agent for review,
a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented Free Writing
Prospectus without the Agent&#8217;s consent, such consent not to be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Filing of Agent
Free Writing Prospectuses</U>. The Company shall not take any action that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a Free Writing Prospectus prepared by or
on behalf of the Agent that the Agent otherwise would not have been required to file thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Copies of Registration Statement and Prospectus</U>. After the date of this Agreement
through the last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may
be electronic copies) of the Registration Statement and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule
424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at
any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then
amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus is
delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with
the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable); and if the Company decides to amend or
supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or
supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance; provided, however, that if during such same period the Agent is required to deliver a
prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Blue Sky Compliance</U>. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale
under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such qualifications,
registrations and exemptions in effect so long as required for the distribution of the Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any
such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such exemption
relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the
Company shall use its commercially reasonable efforts to obtain the withdrawal thereof as soon as practicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Earnings
Statement</U>. As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal
quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 under the Securities Act, which requirement may be satisfied by publicly filing or
furnishing the required information on EDGAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Listing; Reservation of Shares</U>. (a)&nbsp;The Company will maintain the listing of
the Shares on the Principal Market; and (b)&nbsp;the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Transfer Agent</U>. The Company shall engage and maintain, at its expense, a
registrar and transfer agent for the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Due Diligence</U>. During the term of this Agreement, the Company will reasonably
cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers,
during normal business hours and at the Company&#8217;s principal offices, as the Agent may reasonably request from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)
<U>Representations and Warranties</U>. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i)&nbsp;an affirmation to the Agent that the representations and
warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be
disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto); and (ii)&nbsp;an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true
and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the
Prospectus as amended and supplemented relating to such Shares). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Deliverables at Triggering Event Dates; Certificates</U>. The
Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement
relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to <U>Section</U><U></U><U>&nbsp;4(a)(ii)(B)</U>), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of
documents by reference into the Registration Statement or Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) the filing with the Commission of an annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> or a quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (including any Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> or Form <FONT STYLE="white-space:nowrap">10-Q/A</FONT> containing
amended financial information or a material amendment to the previously filed annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q),</FONT> in each case, of the Company;
or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) the filing with the Commission of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company containing
amended financial information (other than information &#8220;furnished&#8221; pursuant to Item 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or to provide disclosure pursuant to Item 8.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No.&nbsp;144) that is material to the offering of securities of
the Company in the Agent&#8217;s reasonable discretion; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(any such event, a &#8220;<B>Triggering Event Date</B>&#8221;), the Company shall furnish the Agent (but in the case of clause (C)&nbsp;above only if the Agent reasonably determines that the
information contained in such current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company is material) with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel,
substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A)&nbsp;confirming that the representations and
warranties of the Company contained in this Agreement are true and correct, (B)&nbsp;confirming that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set
forth in <U>Section</U><U></U><U>&nbsp;5(a)(iii)</U> hereof, and (C)&nbsp;containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this <U>Section</U><U></U><U>&nbsp;4(o)</U> shall be
waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares
hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date
when a suspension was in effect and did not provide the Agent with a certificate under this <U>Section</U><U></U><U>&nbsp;4(o)</U>, then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to
such instructions, the Company shall provide the Agent with a certificate in conformity with this <U>Section</U><U></U><U>&nbsp;4(o)</U> dated as of the date that the instructions for the sale of Shares are issued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Legal Opinions</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to
which the Company is obligated to deliver a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause to be delivered (i)&nbsp;a negative
assurance letter and the written legal opinion of Foley Hoag LLP, counsel to the Company and (ii)&nbsp;the written legal opinion of Elmore Patent Law Group, PC, intellectual property counsel to the Company, each dated the date of delivery, in form
and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then
amended or supplemented. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered
opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such
Triggering Event Date). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Comfort Letter</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering
Event Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause
PricewaterhouseCoopers LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of
delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required on the
Triggering Event Date specified to the extent that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus. If requested by the Agent during a
period in which there is an outstanding Issuance Notice or prior to the next Issuance Notice, the Company shall also cause a comfort letter to be furnished to the Agent on the date of occurrence of any material transaction or event requiring the
filing of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> containing material amended financial information of the Company, including the restatement of the Company&#8217;s financial statements. The Company shall be required to
furnish no more than one comfort letter hereunder per each filing of an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or a quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Secretary</U><U>&#8217;</U><U>s Certificate</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering
Event Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> for which no waiver is applicable and excluding the date of this Agreement, the Company shall furnish the Agent a
certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i)&nbsp;certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the
Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in
full force and effect on and as of the date of such certificate, (ii)&nbsp;certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and
(iii)&nbsp;containing any other certification that the Agent shall reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Agent&#8217;s Own Account; Clients&#8217;
Account</U>. The Company consents to the Agent trading, in compliance with applicable law, in the Common Shares for the Agent&#8217;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Investment Limitation</U>. The Company shall not invest, or otherwise use the proceeds received by the Company from its
sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Market Activities</U>. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected to
cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its Affiliates to, comply
with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (&#8220;<B>Rule 102</B>&#8221;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section
(d)&nbsp;of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of its Affiliates to, comply with Rule 102 as though such exception were not available but the
other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d)&nbsp;of Rule 102. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Notice of Other Sale</U>. Without the written consent of the Agent, the Company will
not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any
rights to purchase or acquire Common Shares, or effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Shares, during the period beginning on the third Trading
Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice; and will
not directly or indirectly enter into any other &#8220;at the market&#8221; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement; provided, however, that such restrictions will not
be required in connection with the Company&#8217;s (i)&nbsp;issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards, or the vesting and settlement of the
foregoing, pursuant to any employee or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules or other compensation plan of the
Company or its subsidiary, whether now in effect or hereafter implemented, (ii)&nbsp;issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other equity
awards outstanding at the date of this Agreement, (iii)&nbsp;issue or sale of Common Shares or securities convertible into or exchangeable for Common Shares as consideration for mergers, acquisitions, other business combinations, collaboration
agreements or strategic alliances occurring after the date of this Agreement which are not issued primarily for capital raising purposes; provided, however, that if any Issuance Notice is pending, the Company will not issue Common Shares pursuant to
clause (iii)&nbsp;of this<U>&nbsp;Section 4(v)</U>&nbsp;while such Issuance Notice is pending if, following such issuance, the number of Common Shares issued or issuable in connection with all such issuances pursuant to clause (iii)&nbsp;would
exceed 10% of the aggregate number of the Common Shares outstanding as of the date of this Agreement; and (iv)&nbsp;modification of any outstanding options, warrants or any rights to purchase or acquire Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5. CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Conditions <U>Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</U>. The
right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the
applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Accuracy of the Company&#8217;s Representations and Warranties; Performance by the Company</U>. The Company shall have delivered the
certificate required to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> on or before the date on which delivery of such certificate is required pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U>. The Company shall have performed,
satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in
<U>Section</U><U></U><U>&nbsp;4(p)</U>, <U>Section</U><U></U><U>&nbsp;4(q)</U> and <U>Section</U><U></U><U>&nbsp;4(r)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>No Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or
directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions
contemplated by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Material Adverse Changes</U>. Except as disclosed in the Prospectus and the Time of Sale
Information, (a)&nbsp;in the judgment of the Agent there shall not have occurred any Material Adverse Effect; and (b)&nbsp;there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading
or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating
organization&#8221; as such term is defined for purposes of Section&nbsp;3(a)(62) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>No Suspension of Trading in
or Delisting of Common Shares; Other Events</U>. The trading of the Common Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without
limitation the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Principal Market or any of its constituent markets. There shall not have occurred (and be continuing in the case of occurrences
under clauses (i)&nbsp;and (ii) below) any of the following: (i)&nbsp;trading or quotation in any of the Company&#8217;s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities generally
on the Principal Market shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or the FINRA; (ii)&nbsp;a general banking moratorium shall have been
declared by any federal or New York, authorities; or (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial
markets, or any substantial change or development involving a prospective substantial change in United States&#8217; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it
impracticable to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documents Required to be Delivered on each Issuance Notice Date</U>. The Agent&#8217;s obligation to use its commercially reasonable
efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive
Officer, President, Chief Financial Officer or Principal Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate (which certificate
shall not be required if the foregoing representations shall be set forth in the Issuance Notice). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Misstatement or Material Omission</U>. The Agent shall not have advised the
Company that the Registration Statement, the Prospectus or the Time of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s reasonable opinion is material, or omits to state a fact
that in the Agent&#8217;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Agent Counsel Legal Opinion</U>. The Agent shall have received from Cooley LLP, counsel for Agent, such opinion or opinions, on or
before the date on which the delivery of the Company counsel legal opinion is required pursuant to <U>Section</U><U></U><U>&nbsp;4(p)</U>, with respect to such matters as Agent may reasonably require, and the Company shall have furnished to such
counsel such documents as they request for enabling them to pass upon such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. INDEMNIFICATION AND CONTRIBUTION
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Indemnification of the Agent</U>. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and
each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may
become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in
settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required
to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or
filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading and to reimburse the Agent and each such officer, employee and controlling person for any and all documented expenses (including the fees and disbursements of
counsel chosen by the Agent) as such expenses are documented and reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim,
damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement
or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or
the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in subsection (b)&nbsp;below. The indemnity agreement
set forth in this <U>Section</U><U></U><U>&nbsp;6(a)</U> shall be in addition to any liabilities that the Company may otherwise have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification of the Company and its Directors and Officers</U>. The Agent agrees
to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any
loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation,
or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a
material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has
used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; but, for each of (i)&nbsp;and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue statement or
omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment
or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information set forth in the first sentence of the ninth paragraph under the caption &#8220;Plan of
Distribution&#8221; in the Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and all expenses (including the fees and disbursements of one counsel chosen by the Company) as such expenses are
reasonably incurred by the Company or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set
forth in this <U>Section</U><U></U><U>&nbsp;6(b)</U> shall be in addition to any liabilities that the Agent or the Company may otherwise have. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notifications and Other Indemnification Procedures</U>. Promptly after receipt by an indemnified party under this
<U>Section</U><U></U><U>&nbsp;6</U> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U>, notify the
indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity
agreement contained in this <U>Section</U><U></U><U>&nbsp;6</U> or to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends
to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the
indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action
include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different
from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of
such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#8217;s election so to assume the defense of such action and approval by the indemnified party of counsel, the
indemnifying party will not be liable to such indemnified party under this <U>Section</U><U></U><U>&nbsp;6</U> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the
indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate
counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the indemnified party (in the case of
counsel for the indemnified parties referred to in <U>Section</U><U></U><U>&nbsp;6(a)</U> and <U>Section</U><U></U><U>&nbsp;6(b)</U> above), (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party
to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the
indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Settlements</U>. The indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U> shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or
expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by <U>Section</U><U></U><U>&nbsp;6(c)</U> hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30
days after receipt by such indemnifying party of the aforesaid request; and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party
shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could
have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the
subject matter of such action, suit or proceeding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Contribution</U>. If the indemnification provided for in this
<U>Section</U><U></U><U>&nbsp;6</U> is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate
to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement; or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or
expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be
deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent. The relative fault of the Company,
on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to
information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in <U>Section</U><U></U><U>&nbsp;6(c)</U>, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set
forth in <U>Section</U><U></U><U>&nbsp;6(c)</U> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this <U>Section</U><U></U><U>&nbsp;6(e)</U>; provided, however, that no additional
notice shall be required with respect to any action for which notice has been given under <U>Section</U><U></U><U>&nbsp;6(c)</U> for purposes of indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this
<U>Section</U><U></U><U>&nbsp;6(e)</U> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this <U>Section</U><U></U><U>&nbsp;6(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, the Agent shall not be required to contribute any amount in
excess of the Selling Commission received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, each officer and employee of the Agent and each person, if any, who controls the Agent within the
meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the
Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7. TERMINATION&nbsp;&amp; SURVIVAL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Term</U>. Subject to the provisions of this <U>Section</U><U></U><U>&nbsp;7</U>, the term of this Agreement shall continue from the date
of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination; Survival Following Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement,
upon ten (10)&nbsp;Trading Days&#8217; notice to the other party; provided that, (A)&nbsp;if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with
<U>Section</U><U></U><U>&nbsp;3(b)(v)</U> with respect to such Shares and (B)<U>&nbsp;Section</U><U></U><U>&nbsp;2</U>, <U>Section</U><U></U><U>&nbsp;3(d)</U>, <U>Section</U><U></U><U>&nbsp;6</U>, <U>Section</U><U></U><U>&nbsp;7</U> and
<U>Section</U><U></U><U>&nbsp;8</U> shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In addition to the survival provision of <U>Section</U><U></U><U>&nbsp;7(b)(i)</U>, the respective indemnities, agreements,
representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent
or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any
termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8. MISCELLANEOUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Press Releases and Disclosure</U>. The Company may issue a press release describing the material terms of the transactions contemplated
hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> with this Agreement attached as an exhibit thereto, describing the material
terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such
disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation, any disclosure required in reports filed with the Commission
pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party
seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to
making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (i)&nbsp;the transactions contemplated by this
Agreement, including the determination of any fees, are <FONT STYLE="white-space:nowrap">arm&#8217;s-length</FONT> commercial transactions between the Company and the Agent, (ii)&nbsp;when acting as a principal under this Agreement, the Agent is and
has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii)&nbsp;the Agent has not assumed nor will assume an advisory or fiduciary responsibility in
favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation
to the Company with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv)&nbsp;the Agent and its Affiliates may be engaged in a broad range of transactions that involve
interests that differ from those of the Company, and (v)&nbsp;the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting,
regulatory and tax advisors to the extent it deemed appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Research Analyst Independence</U>. The Company acknowledges that
the Agent&#8217;s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and as such the Agent&#8217;s
research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions. The Company
understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt
or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Notices</U>. All
communications hereunder shall be in writing and shall be mailed, hand delivered, sent via electronic mail (if applicable) or telecopied and confirmed to the parties hereto as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT STYLE="white-space:nowrap">786-5719</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Daniel I. Goldberg, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enanta Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4 Kingsbury Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Watertown, MA 02472 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Matthew P. Kowalsky </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foley Hoag LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport West </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">155 Seaport Boulevard </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Boston, MA 02210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Stacie S. Aarestad </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this
<U>Section</U><U></U><U>&nbsp;8(d)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Successors</U>. This Agreement will inure to the benefit of and be binding upon the parties
hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in <U>Section</U><U></U><U>&nbsp;6</U>, and in each case their respective successors, and no other person will have any right or obligation
hereunder. The term &#8220;successors&#8221; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Partial Unenforceability</U>. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall
not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be
deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing Law
Provisions</U>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or
based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case
located in the Borough of Manhattan in the City of New York (collectively, the &#8220;<B>Specified Courts</B>&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement
of a judgment of any such court, as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such
party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit,
action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>General Provisions</U>. This Agreement constitutes the entire agreement of the parties to this Agreement and
supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an
original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file (including any electronic
signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable law, e.g., www.docusign.com). This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived
unless waived in writing by each party whom the condition is meant to benefit. The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Immediately Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENANTA PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jay R. Luly, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Jay R. Luly, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald Lynaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Donald Lynaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ISSUANCE NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: [__________] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> between Enanta Pharmaceuticals, Inc., a Delaware
corporation (the &#8220;<B>Company</B>&#8221;), and Jefferies LLC (the &#8220;<B>Agent</B>&#8221;) dated as of July&nbsp;2, 2026. The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date that the Registration Statement Expires: _________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Delivery of Issuance Notice (determined pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(i)</U>): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Issuance Amount (equal to the total Sales Price for such Shares): $_______________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of days in selling period: <U></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First date of selling period: <U></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Last date of selling period: <U></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Settlement Date(s) if other than standard T+1 settlement:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be
withheld in the Agent&#8217;s sole discretion): $ ____ per share </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comments:
<U></U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Company </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay R. Luly </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harry R. Trout III </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew P. Kowalsky </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Agent </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Donald Lynaugh </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Magarro </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d123412dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g123412dsp46.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seaport West</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">155 Seaport Boulevard</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02210-2600</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">617 832 1000 main</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">617 832 7000 fax</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 2, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enanta
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4 Kingsbury Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Watertown, MA
02472 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Market Offering </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel
to Enanta Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<B>Corporation</B>&#8221;), in connection with the issuance and sale of shares of the common stock, $0.01 par value (the &#8220;<B>Common Stock</B>&#8221;) of the Corporation having
an aggregate offering price of up to $75,000,000 (the &#8220;<B>Shares</B>&#8221;), which the Corporation may issue and sell from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the
&#8220;<B>Securities Act</B>&#8221;). The Shares are being offered pursuant to the Corporation&#8217;s shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed with the Securities and Exchange Commission (the
&#8220;<B>Commission</B>&#8221;) on February&nbsp;11, 2026 and declared effective on February&nbsp;20, 2026 (the &#8220;<B>Registration Statement</B>&#8221;) and the related prospectus supplement dated July&nbsp;2, 2026 (the &#8220;<B>Prospectus
Supplement</B>&#8221;). The offering and sale of the Shares are being made pursuant to the Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>, dated July&nbsp;2, 2026, by and between the Corporation and Jefferies LLC
(the &#8220;<B>Sales Agreement</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have examined copies of the Sales Agreement, the Registration Statement, the base
prospectus that forms a part thereof and the Prospectus Supplement and such matters of fact and questions of law as we have considered appropriate for purposes of this letter. We have relied upon the certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws</FONT> of the Corporation in effect on the date hereof, as and in the forms certified to us by the Corporation. We have relied upon certificates and other assurances of officers of the Corporation and others as to
factual matters without having independently verified such factual matters. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to authentic original
documents of all documents submitted to us as copies and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness of such
documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion as to any law other than the General Corporation Law of the State of Delaware. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>ATTORNEYS AT LAW</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">BOSTON | NEW YORK | PARIS | WASHINGTON | FOLEYHOAG.COM</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enanta Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;2, 2026 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing and the other matters set forth herein, it is our opinion that the Shares have been duly authorized by
the Corporation and when issued and paid for in accordance with the terms and conditions of the Sales Agreement in the manner contemplated by the Registration Statement and the Prospectus Supplement, the Shares will be validly issued, fully paid and
nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is to be relied upon only in connection with the offer and sale of the Securities while the Registration
Statement and any and all required post-effective amendments thereto are effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being delivered solely for the
benefit of the Corporation and such other persons as are entitled to rely upon it pursuant to applicable provisions of the Securities Act. This opinion may not be used, quoted, relied upon or referred to for any other purpose, nor may this opinion
be used, quoted, relied upon or referred to by any other person, for any purpose, in each case without our prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
opinion is based upon currently existing statutes, rules and regulations and judicial decisions and is rendered as of the date hereof, and we disclaim any obligation to advise you of any change in any of the foregoing sources of law or subsequent
developments in law or changes in facts or circumstances which might affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion letter
shall be interpreted in accordance with the Core Opinion Principles jointly issued by the Committee on Legal Opinions of the American Bar Association&#8217;s Business Law Section and the Working Group on Legal Opinions Foundation as published in 74
Business Lawyer 815 (2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consent to your filing this opinion as an exhibit to the Company&#8217;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> filed on or about July&nbsp;2, 2026 for incorporation by reference into the Registration Statement and to the reference to our firm in the Prospectus Supplement under the heading &#8220;Legal Matters.&#8221; In
giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FOLEY HOAG <SMALL>LLP</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stacie S. Aarestad</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">A Partner</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>enta-20260702.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 7/2/2026 11:27:48 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:enta="http://www.enanta.com/20260702"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.enanta.com/20260702"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="enta-20260702_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="enta-20260702_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>enta-20260702_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 7/2/2026 11:27:48 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>enta-20260702_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 7/2/2026 11:27:48 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="enta-20260702.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g123412dsp46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g123412dsp46.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X ),# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_B@ H *
M/SL_X*8_M=?$[]C3X&^#?B-\(_"O@?QIXQ\5_&7P5\-;;PYXW;6I(=2MO$MG
MK]U+;Z'9:'JFB75QKEQ-I-O:6MQ<:FEEIR7,M]<V6I");1_USP9X R7Q$XFS
M'*,^QV9Y=EV X=S+.9XS+%AU*C/!U<)3C/$U,30Q-.&&A'$3J3A&BZM9PC3A
M5HW=1?B_CGXC9]X9\*Y7G/#>7Y3FF:9CQ+EN24\%FTL5R5J>,P^.KSCA:>$K
MX:I4Q4GA(TZ<I5E3HJ<JLZ5;E5-_?7AR]U?4O#VA:CX@T0^&M>U#1M+O=;\.
M'4;76#H&KW5E!/J6B'5K$"RU0Z5>236)U&S M;WR/M-N!#*E?E>+IT*.+Q5'
M"XGZYA:6(K4\-C%1J8=8NA3J2C1Q/U>K>K0]O34:OL:C=2ES\D_>BS]>P57$
MU\'A*^,POU'%UL+AZN*P7MZ>)^IXFI2A.OA?K-*U+$?5ZKE1]O2_=U>3VD/=
MDC9KG.H* /QG_;6_X*U^)?V6/VO_  9^Q;\+?V)_C/\ M;_%GQK\%5^-^GV'
MPF\6>$-'NXO#47B+Q%X?U2)M,\1Q+)*=(;05O+N[6[6-H]1MH8HFE5@VL*:E
M%R<U!*7+JF]6KG-5Q#A45.-*523BI>ZTG:[3T>KM97?F>E?LB_M\_M0?M%?&
M*'X;?%G_ ()@_M.?LF^$)/"NOZ^_Q=^+'B3P+JGA&+5-(ETR.P\+M:>'I7U$
MZIKRWUS)82 >0BZ;<B4Y9*)PC%752,W?9?\ #E4ZLYMJ5&=-6WEU]+*WWM/7
M1/6WZ+_$#XF_#?X3Z!)XK^*?Q!\$?#3PM%,EO+XE^('BS0?!N@17$H8QP2:Q
MXBO]-TY)I K%(FN0[A6*J0#6:3;LDV^R5W]R-G*,=9-)=VTOS(/AW\5OA=\7
M]#;Q-\)OB3X!^*'AM9S:MXA^'?C'P[XVT-;E5#-;MJWAK4=3L!.%(8PFX\P*
M02N*&FG9II]FFG^(1E&2O&2DN\6FOO1MOXP\)1>*H/ DGBGPY'XWN=$D\2VW
M@U];TQ/%5QX<BO#I\OB"#P\UT-7ET2*_!L9-5CLVL$O ;9IQ-\E(+J]KJ]KV
MOK;O;>QJ:KJNEZ%IFH:UK>I6&CZ-I%E=:EJNK:K>6^GZ9IFG64+W-[?ZA?W<
MD-K965I;QR3W5U<RQ06\,;RRR(BLP-]A[;GB,?[5O[+DK(D7[2?P"D:5D6-8
M_C%\.W:1I"%14"^(B79V("!02Q( !)%5R3_EE_X"_P#(CVE/^>'_ (%'_,]5
MTOQQX*USQ%XB\(:+XO\ "^L>+?" T\^+?"^EZ_I.H>(O"XU: W6EGQ%HEI=S
M:EH@U*V!N-/.IVUJ+R >;;>9'\U*S23::3V=M'Z,I--M)IM;I-77JN@NK>-_
M!>@Z_P"'/"FN>+O#&C>*?&#W\?A'PUJVOZ5IVO\ BF32[<76IIX<T>\NX=1U
MQ].M2+F_73+:Z-I 1-<"./YJ5GKIMOY>H-I-)M)O9-J[]%U.GH&% !0 4 <7
M\1?B+X'^$G@?Q-\2?B3XFTKP;X%\&Z5/K7B7Q+K4Y@T_3-/@*H7?8LD]Q<W$
M\D-GI^GV<-QJ&IZA<6NG:=:W5_=6]O+Z.491F>?9G@LGR?!5\PS/,:\<-@\'
MAX\U6M5G=V5VHPA"*E4JU:DH4:%*$ZU:<*4)SCY>=9UE7#N58[.\[QU#+<JR
MW#SQ.-QN)DXT:%&%E=I)SJ5*DW"E1H4HSKXBO4IT*%.I6J0A+^?O5O\ @J/^
MW5^V9XJUWPK_ ,$T?V97/@'1+Z73+KXV?$_3[1A)<1;I!-YFO:QH/P\\)SS6
MYCN8O#VI:AXT\2S61BN)-,T^XN/L,/\ 5^'\$/##PZP.$QWC-QHEFN)I1KT^
M&LDJU+J$M'!K"X?%9MCHQFG"6+H4LNP<:MXJM5A'VLOXZQ/C[XL^)N88S+_
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MY?=4I26CDWYK6RZ?=ZX48+$.5:JE-<[5*$K.,(KK;9M];F5_P4__ &??AO\
M\$B_B)^S=_P4Y_87\(Z+^S[:C]H+X;? K]KOX(_"^RMO!WP>^.GP6^*5]<Z;
M)?:S\/=)2W\)V/B[POJ5G$NB:SI.BVUS'J.KVFOR[[[0T>Z=)NJI4YWE[KE&
M3=W%QLW9OHUOKM==15H1H2A6IVA><8U(Q5HSB[VO%:)^=O/?4^M_%JQ/_P '
M(WP?N%$;LW_!(GQL$E"J7,3?M03, 'QNV,?FVYVYYQDU*_W>7_7U?^DHT?\
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M$[ZAJ>B^-)+;4M3CU;68([*\5+>\LK_;!J.+<2-]E6\#N'JOA<^ N&^-/JF
MSGB+_619QF&&PV,JYDZ%&EAU@E1HXG+HSHT7A\-.56GS3IU*7O4O?:7PE'Z0
MG$U#Q=7B'Q1P(\;C\BX97"\\FR_$8O+J66>WK5L1]?\ ;8C#YK*%2K'%8V,:
M=11C6I5]*O[N,DO_  4+_;O_ &0?VWO"&A_$WPEX#^*?P#_;%^%VI:#<^&_$
M-SIFCW%EXLT.SU*WEG\.:AXP\+ZQ_:=KJOAB>0>*/!&O:MH=G/IE[IEWI44E
MG!KCO >$?A=X@^&N88K),?F>1\5^'F>4<5#&X2G7KQJ8#$U*,U#&TLOQV']A
M4H8R,?J6986ABJD:U.M3KRC4EAE&;\:/%_PS\4\LPO$&6Y5GO"/B9P_6P=3
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MIOW;VV;CS1:>S72_Y,Z(U*5>FES\CTYHJ7).+6ZZ-+L^J/,?^"".LSW?PO\
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I%E=ZYK%Q;)%-J=Z\XVWNV^NKOKW_  7W#22V27HDN_;U?WLZVD,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 02, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENANTA PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001177648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  02,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3205099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4 Kingsbury Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">607-0800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENTA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d123412d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d123412d8k.htm">d123412d8k.htm</File>
    <File>enta-20260702.xsd</File>
    <File>enta-20260702_lab.xml</File>
    <File>enta-20260702_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d123412d8k.htm": {
   "nsprefix": "enta",
   "nsuri": "http://www.enanta.com/20260702",
   "dts": {
    "inline": {
     "local": [
      "d123412d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "enta-20260702.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "enta-20260702_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "enta-20260702_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-07-02_to_2026-07-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d123412d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-07-02_to_2026-07-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d123412d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.enanta.com//20260702/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-26-294837-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-294837-xbrl.zip
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MEI74SO,7:6>^"-72"GJM[;5D?%B>_X[VFM3P37JN17($S?KTT/FZ'BW<NF:
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MBE!='V)/TPT<7\R:KO6J.(:N#=<B?.8)]PF'306R*\AY;YE-)Q#@EH.8\F3
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M\6=^_'S!+J+7<]D[Y!/KBX"*T-H,0YN;ZM!BIDV17?,I+C4H%2/[1 A#P5D
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M!/<)]A.^RF,[2"[D$.D)D>_JY/9 !2S6,]P+?]S"CX)Q=9GJYZ,_T1CU;R@
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MG[A(3M^JT;DA>QYF/Q[A2(OI&F.[3C,$&B"6KH'+Y%]//G#@[,U,07VDL;B
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MA60@*P/@]2TQD6Z8.PB.'"1G)G4S$//;]>BH]H)CT3XRM[F:A1ID3>/8@Q@
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MZR;/C =VX)+X*!AV#3I\GK;T^38("EC,,H.3R7&5!Z_DJ6B@D&:?WW+XQCU
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M 1>N(,2X_'"]E@JC)!$P9*8FLB*&E2S!7I!3TM\:/G^.(-$"!:1.@D3/!$6
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MSXNQT31;/UD]%_$K(UC(HJG<NX;7YZI:P(* ,X1E0PUX' FJ#A[:>'1=:9,
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M;Q>WDHW>.S(WI =/6MQDIW#4ZB;<\ !I1*MX;!^:MY[_T]:\6!GC?*GF\YL
MH"U.+V5VG'/L/1&MO"VD,:S9+0.3DQLI '9S=#<@L*SJ4+8(-Q4"OJF%:K'$
MDE8WFG,WFK"GD4 V>&,L\0/Y>!E8J>!U8 \"C-2I8'5K2F"!_160B/)_PEA)
M/#?\'AE8TCNNX#YA#/KQ$RQ]'")S@NNL>Y*(&KMSE.SC\$O\\^/#7X9)K#YC
MD-GQE_CB7U!^&PE??%.=. R0LE5LRD$*T,HANRA"D8=NNX>+B9IQ+HXIQKKE
M(BLVZB6N1D$9:3@N1@(WFAYD>4'EY@8H%Z/M(:YD*WA5T1TI4R3%Z"WIC01V
M@D3OCVERG)&/Y;?'N.+#-+KD;[GG!M/2G(I1,/*%@1!FD-WHG253I6V?V>8!
MP[RWSVV2(YVK%JK22^C"OP['YS(G_H9RK.["9 1G 5Y,]0><BU0CRCW:$GML
M7NH=* DW;)TE.?R0O9,9\62P/C8OM0-.-+5UXT1R*%[=X6!.S2M\%].&*X.6
MA%%2=*5-Y;(QH+XX_.4?ZTIR?KHA-'.)S.*'(ZJH7*]P H\Z!XQ;\N*#,618
MU:[BR5L-,Z;"=9#ON7V]SH?$6/J5NJ\76(=FI,1.6"N07:6KL-9044XD9&QM
MD[KV(1(C<EG+/&AXCKIE$*XX=(*@/*T$17H["H_3YQ?%O!6=P@82/Q>MO:ID
M.#IA<S$6"IK7Z;C%[4;T(0_<(BI=R-M5?PQ8"H^9N-8ET]->PV$\$HKQ<*8]
ME:^$["20J%<P2LI%GEID?4HQ$2Z&'2'LF@XPN<GKW%NOA?%^Q._HJ(M/!ODX
M"=,ZYS9FWU$"^ GF\8MNX(!5[H6$0:\]]*9"0B/AQA-7F2H)I?^I]&J /;>-
M?7QV&]WJI9Q\JZ7"T365QPZ97SL,F=KZ8*!C3[IU;BC-*?CDX#M(KT['%\Q_
M"K]QT\/H R;[7LJYH)[I[W*?Z#'9#RQ+=H<*N2<4 # M:G!S$4:%X)J;J[R,
MIU#$)2<.RU:G-#7/E<Y>S=QE!)CB*@RH#A./T;I[;-M==R "21O RR*[,8'W
M_A+6'G6Q9SR;;7&MV:[4(4_VY@+DD4[U9/:)XR@^4E^?%GSR?%V717.5D!:#
MI;HI'1 Z J#Y<X5DE,W&<V4EU_+^=P2!]*XC[0[V(I_YQJG_,I(^'JFH)_<N
MZ5QDT'?D V;S:)&$;VU83*-,7TQ:;+N=Q'%[KAY',XRZ'7C\4.HOYR&+2R_$
M$@R9=DU[<),1V%'-KGZ@11>!?N_GY).ATVA]=4@\8?D)FQ)C2I*PT76UHKX;
MPU<9S^*-EJ#0'CC+53^UC1<\:C6[W8G8[QJY5'QN'C)H?VO-I^OF8(Q%CLL%
M,= X/KG?%Y15W144%,[)3>7T;A9FS1E@B7+'#!*F@&>E:Q[QJB,/;R,<Z"3V
M(-$KDET*C6D_9?[NP.0]>+<+ ";=+"]Q1VK; UV6MR>+3I.2DYM*J;(>9'PA
MAYO7I6DXA4^[RA?<19J-&?4$%MDM%::4I+L&+Q(3)S.Z1^O"+"?!3K$W<2!4
MQ'I#Y6$R44S7SSBN]OA+7.U>%6Y."O</]ML'?/;-?=^\2B$.!L&>"= L#2!F
ME>FNB7_38GQG@JV;7+[1^7@:G&93W!F=:<-"T;B@EL3E_=^6RW4I@"-%FDA+
M);V'3;=G+%MWD4!_X QSB^/;ISKK@'%_:S^$#GP]@+ $B&?R'L.*;:<,!P8I
M1 5V%X3D*&L"+-C@WL<UWP]J#\RY/*%_;'WP]0^X\9*=+SQ"&.UVX[GO;8B#
M;38$N"R1=?DF1&>R&Z!SR^6:)JY]HIP^N5UH%N/11TYC^"8.[N#D(Z_@767!
M*Q/$"F&K=*+#H$C^RC?:'I[VQ@UAT8BSEZDRT/JJ4#,SR1AP$,7P=Y&O%.0T
MBVZ&.L[);:O,C9-\1]\]!LM[GU?<.3#]^"G)O(:E$<AE+ TW.?I3A+-0LY;K
M/*R;U9^HV6?!X?"1$"W2O]'"EU?0KE_GBVJU%&1&EL3QI$V!Z,X6CD=W/U08
M0 0[KN4A,G&E_JZ7K\XS0*N7/QSYM]%F?O2'^??!Z"*'?SRZ[]A6C\./.0-&
M&S S5M8RL U$7EA*NM&LKJKRB;J>@!1ICZ&MAAGD>  H;X NNO8^4)W#^Q7%
M%<* S,87?#;A&<$<W6&W7!?QC;LEJ@WY?H16:)BJ8K7='7=6S<""?XB7"X[M
M!UWZ.WFY/?YHCR ,V6@?<C7[H%+/B^RR!1"4![N''QK'=LF&HLN#"P?7G2U'
MFC >(*ZNEWRBZ^+NFTL'476[>6IP>V=\,![01=L\QHMX@\>_XVT&AJJQ2,Q8
MHWI_'_'GZ;E^6<1^VIE#ZRHV/^,(PI,O$81[/7E70BRI=O.&_K)Q2&$;7@?3
M11Y5N,A\JT5A0'LPHSBYJTW<GP2O_"WESB ]0=R./39;B=\7^]O[@A+^@.L?
MMV&1&8O8AQ"9!>^2)T59WNC;_=Z<;917E$'NEJ..VY1=S_Y(&GT\VA+U3)G$
M6"VR?^ C7=_<;>Y5ES7\J2ND(S&TU/%#\C6HG:O:_,V5]A&!0J>,#Z7B3_AE
M,RM8D"QB0Z@M YMD"]FF8:W81C"VM2=:W<>23:[;W%F$ M!2?P]#?\Y9ZW7%
MN@E-^$V)V88!H_DC'!YC,1.OXE_NX/"V&P@1 4&X5?I5+J(:9#N-E]V7R2>)
M=( @"G:R-'<@$L):(JAH!V/?,7'/\D67>W]"B0:@</S-3<;CC*Y97I-U[8,
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M3C:(2296 AC ,L^Y+L.B"YK>O4KZMNHSKK+\_DMXZE[ODFNZ2S1\,]?&5J!
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MIQV#IDHQWMD?;SV=J& Z2!PM+RG6 *J78;H3""Y#6C(@JB4_/1OPHY@:A67
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M[-)0<4Q[632'J[@RF%@(56V^N@A<< H$ON7;NK2/XF*NZK+5SNV(!1O,1-O
M<-B$"Y9L%2)J>PW36'D/#;L;(VEF4:D#+*?#C3=>3*4OX#<1:1L5<P0>2=,
M/S[91,I"JBZ\2C=?+UB!'(RW I4###?>(*Z>5?;TX0/^(AU*XGZ2>_ZS%^ U
MM\@$\C\9KV@?T]-XG/O+5&Z@5.Z@2BZAJN.E3@KE:&E[UV:<QR ! :92HU_(
M>@TRE#82X!@WXQ'*YZ#A0WDF$F!H7]8>6 =#S2[ ?%_]4MS-5F6X %DZ=)LK
MUC(336.VF0=#3F:0XG"&>Q9)CUMU;RPE([A<%Q@YEA 05]O(W]$+HF_8  *B
M<S1"JD5<Z\F&&+][#C'>+<2H"&D]] Y'TLWF+,)3S"Q02YTK: _P0VV>A_3!
MF8FC+J@U<[=$:K/  PD[TK1K("'NN=C-#0-;'_5$O8<,8CX3[KK=6N)%"GZC
M0.(2)J4C20#*G#"?XU2R5C_Q:%P!1VS,I&MCTO(9IE]@<R-G-XZ\QXK-XI\/
M>P*U#,F\YU$WJ HX2X'?Q9.WI2$&]32^M9#^W:XJ*2 UWP<ZO?/2C*X3&9MU
M0*YP+:Y9[AQ/ET%?;14H.TN=1#6]M&\I;NJ#BT,7S$3C@K2$/C<9?J5Q3TH'
M:2 "#'A%<[%"Q\<DZ& Z63GN>ILO8)S5#7%[LXHB5$UZB$T<LD836 L*1@38
MIFR>M5F4,\9&1H^#=,)H8V<!\\'FI[_EQ=4P3<#K-LX-0J$+#]J$=#*7L-XF
M:) #I7A1EDSV#P+EN(") ZFA7&0!=-RPW-KM*>MG^"83#-9<AY/GN>N#F4YA
MM2AA)S/R''V*3DC5K-70/ C9?!Y_IRD?@-$%WZQK!%/1_=26"?"P4<2LQ.@H
M!7)!MPF&BG:X4@?SL4QSQB_"<OSV\*EJ K/M8"V50M74@"$^IF;^*)WQ@N"#
M]I*OO%!)/U3$<50TFC4F[)WJ@U8)9H['2E,\4FOG',60S3!PTQ:T'346T1Y<
M%)*R$2F2LN18Z*^3BLLF[/V>#?PIK:N%SC>7!/7U[PPSN\ =&6M3L"B%9(UV
MULA<&@4J$*LO,?.VT&6"WJ360L482XN%$B9.;K <%S"+33%57P_P!NWOJ$70
M3+(T+K2[3#!@'%0HM@?IBLI)R*:$]%1<>XUVR$QSK8$C&.-U#"$]GV1#"CL.
MRGB23(;(#I)5/OU3M-)<NN,Q9VQLK Q:P/:K[NQ0Z"H*"MNE;U%SETY5&2)E
M,(JNF00SF]+6-9"6]TZ+&\TA9X8<BM@5\&J>N_F+GT(NC.6EF]<^!3@)LIVM
M>H@WBK''YV&;Z9#$@=/D]3>H2INK#JPS_U@XZJ:Y*\'D;+WC</![OP(9E3?&
MKM@]WN\=(+<,??;W>'3Y0W3R^?CGWL_=O84II9C=<&JN#SJ+3WRK[L:GXAMW
M)"(WL?PJ] ^9%%9!9Q*,NM6_;P[*;,@!_D3OQOXU2%QD@)[@L+CQYXS+45JM
M.'=H*G!"\/AZ9&UV_YYPF>_+Y_#; Y3YGCIQ0K.A)^67#.!7'ZV:C/K[3)/G
MP21E=C,T_<A/ @"AW2:U/:&S?^V[SNRM<P(:!Z#E>)KT26=YB4A#S?=7-M8Y
M[*<T?:R#ST_C=A2N]<Z#08.[$ZUT_2"HI0J4'E9A%YWJ&UW4 /'-@&$VJ)3"
ML H3QXJPH_X[G69E.HJAHH_X5\7DLX+5LZSY[\PR8C&V9B(WD<N#7/"'U5#)
MK>F1F_/(M4"9Y#S?>SW/E]X(%&I6;]\JM$B%>V6&NB>EZ=0WZ+?(]NROU5 ;
MU@(!@AFD$ ]\R!8[.,'F 91<Q8>T ?R(A[BAC8^_I<V>[OE54F@6R?%C[VYH
M[8RY@P68*7=&16@E?YVEGM91!R+Y'E>L5;J3R!+M6!U4#R/W@SKSG&=N>X&D
MHJ2 QY38,V)6>3,"A_!DB-@Q%F\C4 %JQ\1E,F2WBQ+[-D0D=:=G"/S5 &'7
M+EN/WZSZ0'_,Z+#*4<K2=K%PRJJ.8KQ6XM<1 Q;!BP3VYBH4\P,,_4:<U>19
M)[KK$HM)M&_;H3&1?:9)*6%(+N-K#QJEQ9-]P6;$;,W8IHLF<7R[%NWW3K9W
M]_:Z![N'GT\6:5(#N330>R/.@I;V#NF[3$I%X*TK%DG;$\JLX*<"T6!B'(E3
MV.B[.HBFR/8L+[% $%2G%N09:1)V7UN[31*6:-ROL>#>$T>6($4<;:.2PQA4
MZ8H2B;\_ H/WNX^'!Z?6:+O(QNF+ZC+NIUMY<57&E]^\?_OB'YUWW\*WWLN3
M_8MZ/#8^)E>@@8 N*@514A]R(BW#0VMU]OAP;*2- A6B7!!4MWVF<\E>.J,8
M50ZX&EFFMZKE+")J+C\5$I[T]*GZBAT,JA(>Z1S*P >Q:085:6&TD>KA<;GB
M#B9Z5M4.CD=Z@?,0,@P-\5M)@2("Z^IFT_H<.U%D0M3IQ5J ,,5O<$8;4ZBO
MLB@K2INN+KQ"T7_7<$^7N\0551$-1-/J"T7,_;#!*J>HDH;[PIW;\RR2*8@V
M6W+!CU+&:B0K-;5"3UR]X]@@H!TJFR[*0W5R9WZ\ .W2%)>?D'ZH ?0-4'X<
MCJF]BOU$/S'1:.$/DM9&X\LF%^><;5#R+.PD=ER;6S9,VV[3PRA[#LA1FIY1
MWW,/O]F\$;_=5EN0 H79X5T@5R?YN>ACEDSZ((8.-Q:9<Q?990.S<-\F62O'
M2L'GC*ZKF2TDIY LFHD'KZ$T,#1('0;/53/2,^^4N!Q)!=6+89J?CR_DAG&+
MP&^@+N=LS.]HT?<KP,?Q:N&Z:)&(4,DXU3L5MJ_(0[)9,7Z,,;A0Y,Y_&M.W
M8S(&$79\9@WL;-4L:A:WAXT,"$(T/OMF#V;,^R6\SO;H<SNL$Q9O4),O.!9/
MM6<)*KFA3<G%:'%.-/V\DES;P(> )!&C1R'9,8B_U&+1-8]WKJ-8H/R #S$G
MDC"1LEE@>E(J%P9!O"G#)G2_1%^ J(5(C&I,LH-$D^$9^;DDSXBT?#7( -K$
M&4D7P"^L'@NFSF=U^LD&%5\]!Q7OANF;N=S9=L [T2ZJ2E$7U=DOU?GC1.O]
M3!8<%5WCF0XS#)&Q66(.S/B<";R M2%.HI)$J0;^OF19"I"FPI(KJ(6HQOPY
M%11+>+]P]5+VK,)H5KUA<M[8$)\%AG0D&XU6I*>?&HWC/W#72JCFIN=):/Y?
M$!FY(/[ 8KK*&YH!41#;#GP(-Z0"![]&K,&0.&7L/3X6GGAICM,JC4MCPG3S
M>'A=C9&0!N7E\GZ#?^I=_##!1%@6JI'P,V-Z)ID(]M,$ZD_'+!91^@ER*IE#
MU,09Q9RH+6.;(,I*/RH%$1LT-D5J+LDD586&29EJB!)H(<7H3#CF1*K.0$TT
MDD/K9^*Z67W-L(\PWV$GD=L%(B:@1%I%HGD6P$E5BT'P$U! B6O(MYB\1D$^
M-V#B^32M:!5Z\A+_#9LOY8;1!IQ_'+T5P *-&%>JT2^!64/1MBHM<1,JI4.(
MJWN#2LV"*C7HB_E_#TRFW!+U$&"^[.!(B[B6WM$#MGM@CUK$"@V, K"@&-K$
MV$8C"3;BK T+@H69Y5>.%9E'!C209Q3L0]Q+D^YK'T?',E+Q$4IQ6.K23.?R
M*U J3BQ555_XI[K#(0 U1J-);MFK0F$X@O5*^:Y7]3J*B;3Q MG4A,2F@P6+
M9CG&Q&Q0%N;A^%US1VF/=!6G#[YC/-\T$5XW6$J.S2^(K<051[.JK4?WJB!!
MH53H;M4 _@@,#FS G1KT4XH'@OEP;V][6FO:+)A[;<VKS?5HWUCH@._I?DDA
M[[_H)CF%T8-?(F,F;FXNO$D?XSZ20J5;T<KKEZ]79SNZ;]Z^?O'JS<;WXMXN
MN@?=,:IU%_E6]",+P8I"UV/O2&*7,(?&Y;7H(3ITGJ@9CU-.,J^:[;OX3>OT
MR!8^DZ]>19\F">S77^(RJ1;>GG"[KF\LO$EJL>^ "3",>FO1C\:B.$M+XY_L
M5K]/C>X]2AMGGB"[+^#VW9KC 'G@>Y/-S,5OPMT\SL=Q= 2UMV:D)JB1;&S/
M7MY?_'R^C/X!93]G$^-M?B47Z3\AXS8VEG<GVN]&ZYLOWRS^)E5;<S\>F^5U
M%1VM1?\HKLQ,_G:]\.;=9E<^R<#@Z^? X'^[3?,139I/17S^5=@U)VF,^(1_
M LO)HANS8:PL:="'8@)5P&6R\%9]**IQ(:?YYL;ZPAND3O.3<=S/TNAD+>H"
M4&D<+WZX[M'$:D5)W6RX )6AT1L0E.*4/D;$D@2S^! T4U260:RG%=RKX;A5
M,TIR=OW:6T:>+HH)YF2"!<*%$UFJXPBSG($4T%VNN1?<W)GY)*/B,0(SNW 4
M(:ZP7#M/&GZ."0$GK^N!'Q-/!ZJ."[PI0:%4UB:6_ X!A;4H<&6'@[Z=%Y(8
MYIJL3 IOD-B&I$A*+[]I8X,4-<;B#U: <$\7V0=W:PFS,T*))J59II4K2!+8
MLQ<WMD'GD7GC\+J!2DV>LP!PQ8"P?[ 2XF'T.4]SA)\R@Y)FV_MBS(B$1:LF
MP?<$\M %'EN0N.$Y[BB]#2)4<@#?IBH;+.&-8@Z80QY O;3YE33M<[^8>-HL
M1N@.#:X3)ZFJ5J&0P/8'(P:OP[1_&_,$PGE);3P#\ (=A56T@G!CJZ+B_1'5
M/""%5%=6,KN8FH&08M>*QS_*SG&Q_5A\24LLI=N+KY:7CFS%5N/)9@/TY_@S
MIGRAPZ8"FHBD#?AN,V4D0L8[=,R(48G/Z/2-0*<H!48"$+G,BCE9@)A!T:E@
MNLQ<[)8' (C#.JH^7S&TU92(EI>4%%$=Y3=7#IB3-YG8T5993,3:^L6D=##V
MSWD&W\$AP ^[YD0R74<^6_7K#P4J'\ W]N/\ @"MN?QMF[>>'3YNJ_^F^BCK
MXQQD\6[_PI6^N6'H&A@R=S<?VX"N-A<$$75M8X, 3\UG^*HN "7J!7,O?2GZ
MA'R;G(VRL4J FU.^@IM&2]1%*PQK&'B36P4S0'!]5XZ$.XXUE( EP=+]:=9T
M'$""T8OV'W[NO1^J_699;WF1O[#-7Q4C3JX:GB>M6="^:M?,L4C94<U&66$]
M"JCO51W+$U%:!>((%V8VE%J@Y26?(5RL.0< ";@[*%^*M[Q[N^"F;(%,T&B^
M_=V&$_4.W5/L//-E<"I.KP%8'A[K((!1X\QBHW[EXG4A$"$Y(M,XBFO9V<R@
M9&Q*TWAEAVN5S)XYV\- 1H+:%=$EX,DL)4B]TY3L;9WR^4?/T6-X7T'%BR(W
M Y%Q=<9D]/CWRP7=+YS(F7&QN/!#Q?MT;(Q9I0FEH,O-E;@(C*PF8'*F2%H)
M:%D/98V*6(R+E")B<XB;S_*T0-TU^*,K48H<9 '/%31MTW.SQ]C):0)6!&R6
M8N$$W16LU!]IW]X45TCIB#2PB#E(2^BL55O-4\<FZCBE<\ 79.? 5-Q13&10
MVRXDJ)6HI$!1?CQF8#\GO?-$W#RD K'>"#XAPSO=K^$XTZ(RYG 92-:1+DA%
M @6X,Y>E]TJ'(HA9X"5OSRFB68I6CG8^KE*AR(JOK^F>9:99>F)&RK8$+]4U
MX]O+?;M[TOOQ@-@1!M'F^OIZ!RY=>%&TZQIVJN]UI[OJOG#BA@T&X3@%X\:R
M+M!F?;(AUC?/(=:[82]#OL-T[7S-[,2KJS58VK!0U_K%:+7Q!&"F%U1U)!CQ
MJ$CH$F)* H6/ 4-[. S/01TLR)'%@LLYA;64,9X((1LAI=JJ[&.\O1) 9N&[
MZ#^#5RH#[>J"_6?W$M,C(.(8DU&.,0I6G"9/#IO%SIQI44SG*#<-_*.!-5CY
MMG**<M)#=+$<."AP2=GOL'<GNAFFQ^.I588/&4 +M]B_WO7>VR,D.C(;).J-
MC.,"Z$W3,ZKR-Y=B[_V_G^XQ\O;Y&+GOO/:%)NK/&D.EU\8&](T4]&;-A[%#
M;_]F&@$N%2A\HXUD-L>DS$,@*!E=4(V$4B&7<K@ C3Y*@3O7V#,+$/YH!>NT
MX6)_+M8*ZI['-O+I;+N&KJ'WAR68X7Y5 [GI=D3K!M$; F>:EP)&(7$EO#OM
M?MC;C:#N]^2HN]T[^/%_OUG_!O_[J+NS(__-Z^DE+*</A\<[N\?X,;>*/GEA
MUN!>]^AD=TO^9>I$AZL"5AEMEM/C]_PO._+B-W_[QNRJTQWWAY^Y*]19M^+E
MB_[OO]^4S\W_'*LW21?4ILN0G&TK_E)D273#+@2-,Q-CQO(0AO8 =NO[G\$(
M-.O'K$E8OU7'M<EOCWJP>NZGW=Z/GTY-+U_[CVU[RB/UZMV'][L'W8/3;G3T
MJ7N\W]W>_7S:V^[NG72BWL'V&E62W[*?WFPV]G]S$?U__^%Z2[<L6(YVW]6_
M@;^>^SC=@(_.4.[<??0'U+R9;OQE'?^YX?GZ;?5M]),Q@H[7HKT)Q*V.+M9V
MUO"(>/QAO,,8'AC3<:NQ)T^I%Z= [;<5 >5!EDAQT?9%E@ZB7720(<AR2(DN
M?8"9_X.3^SU9'(_)'''J7<Y>%H*#P0YMCM&&/@0J&T@8%2[11L E;@LB,&/1
M3Z>H'$<R:K&<.]R)SQ?@ JZ*GW8_?MP][NV> +S^^6[XZNZ&'8CO)M'>=1Y/
MSB^>ZKT0]N(I]8#OA/TXC\^1V(VA#4WG?_3L=-Z##P\6[/]]ZGWHG4;=6<Q'
M#Q(HZ9V<?.X>;.]&!X?&=-Z]#1W4C3;ZOX#C[=\/#ZBJUU(]8$#R?DJE;EM;
M(3:,*XAZR GLCL?Y5O2O_]A_'F$RCZVB1L:8!(ZC'%ZFN1GY\K=T')T -:"U
M"M^=?&XPU-Z\,D8GT 9"?< +W/5;>/*=[+_[UOSBO245F591T(GB:"<=QE=Q
MB;J\)62S*#GNI^(YS%//P/NK,_@5VJGZ-TCQE;"-^I-Q.)@NLA-MKF^^]FN^
M'2<F9CLIX99P=:QH ZJL$,:6>A4P,9GA/6 N4 #F( ].9M\[%JHQ3J[!\?^P
M*VV'6$ZY:+F9T=KX*I?FDJJVHO^T_?/PRW.'D1X[:ES#(5U1R"C-?#4'R2AQ
M/*[68>%W#<KQ8X:F42\N4@C-F?MP?=:3X%6SC#^Z7#? )Y!W@JEP3XV_L?=$
MEL%#N4_AE3K%FWJU<4=WZN7;K\.=LLN[2ZH(*^GODWCH"S/!@5Q%1R4L?TN^
M1?!0LYC_VK)=;^>4O6WVR=XNW"4[F(S."!R+XK* FTLM.C@KDJU(]OQ,L_TK
M=M_4P?+GFKZ/& >R8KK/4_=TIFXO?IZYISES 2/X2K4*8"J1T(OS"!.O@"\]
M_9\-):D\1_!KQG3^R0;R3[>\5?CI >WYC\/"F"MDN.Q9OEN Q@':AP0'$;R#
MB_&O&VOKZ_,+IS,S)4$*Y6^$#5I>@J>@]C3C8WVJ+B"<1/;2,H4&@1&%;@^<
M:I#O+],']_ZWD0-K7&UAL9CX*G]YN_']JQ^>_^\'6)^?W]]CHN@9/+$89^<N
M4?2O[=!\3FY]]9/R=2YD3&@]K293!FL*7N$Y:W4_6:L3T'>80,1](6DKTP(.
MK!XQ8EE:\9#6#ZB&J5@[>9 /G<AR.*,'M^X^Q66);SLMP9;M]7H/'SQOX_IY
MA'DD0-"CS**/"GCP#NX;YR).A]%^?&ZFM)!9;#CYS+8YW/G%?/CI='_O_?\#
M4$L#!!0    ( !*GXERCS:/ O0L  +@J   0    9#$R,S0Q,F1E>#4Q+FAT
M;>5::6\:21K^CL1_*)'):%8"&_"5$(P$-K$]P<8"-M[LMZ*[@$KZ2G>U,:/]
M\?N\5=U-<WERV/%*&RF!KJYZ[WK>(S0O1]>]5O.RVSYO%0O-T=6HUVUU_U4Y
MVJLU]\T3EO>3]ZS9Z9]_8IV+LWZO/S@MW5U>C;HE-AQ]ZG5/2X[T1&4FY'2F
M&C=^Z'*GU&+% LZ?"4^)L-4\O_J8;IY+6\T:;_:.I%=BW)%3#P3$1)4TF]MT
MF\O#J?0JR@\:U4"]8\GSV%?*=\W2Q/=4)9)_B49M^3SAKG06C9%T1<1NQ)P-
M?)>#4[MW=7%S6@I)R%*KV6EU'V9R+!6#PJRYWVDU]V];.?XYXG407Q-G0YI2
MZW=O' 7O-!6R9[O3Z[*S;J\WO&V?7=U<G):J)?U\VSX_3Y_OKLY'EZ>E6K7Z
MNL0Z_<%Y=Z#7$QG,2@4V[[5OA]U&^N515=?MDJEN:5^0F6%H$G'02KZ<IX(<
MG[R&;?9'Y\LW'Y/31M6ER.G&50(']70=_PQRK%*5 CX5E7$H^)>*]")IBP:_
M]Z7-OD^EUIIP<(O1"\M7UQ=L.#@[+4UK]8/#6MV.@L/CO<_!E PQ.BWU^A?]
MDH[MI?1K2B:^3#VZN4_S>[Y@;0T%#_Q0L3L1J;6X?&I6M:,CEK+K^+$C[GEH
M$T]H_&Q,.WZD?*_,KMNL6J_7JI7Z<;6Z\P(>YUCN%B%_ Y]3]N/:"7MS4&>X
MM%40D]YW.:CVP_Q.B-^$/Q"[_ W#!V'-#A$T>/VTSG_&SH+5RZQ>K1^SW?H^
M#;.NQSW%BX7;&4<JL42LI,6=J,RN/&OO$>Y/XMU#]D%ZTV@<APO6OA=>+)Z;
MXQT'*BM_KJ]#L5"M'Y[4UWD^23)ZVJ22RU;K66T]Z^6S7"M)!Y%:.(*=LET)
MH;266 Y?+Y7:R#I'R)YY:$XSGBDK!J*1/Y-_MQ/0U^"&_:R;W[$UH=J*J9E@
MUSS\(A3K3R8B1-RQU<N=7NT=</8TUZW';8D5[MGL A6"(USA-1X)^N,=3)5X
M4'"A#1J-P]??>PD$F_%[P;BEA,UXQ"P_]B+A% O*9P80V%8\*#/.SH7#YSP4
M.!0BCW$E?8_]0>;]_=6;>KWZ#M7>V?(5%7OZ1>W=/\I,>CCF><+2I^92S;1C
M9!3%W+.$MDO$$:O^A$60 '+C&VVQ?-?%$60RZTN9_5;=J]98P$-VSQV@Q@9_
MO7E(F_,"I,1R\I$E$ O% O<8GTY#,05"8%\2(D$H+2U-'# 8Y[>3HS(R _U=
MYSG4XJZJ.Y]):[;!T>4+K7&BKG <-@E]ERGXB9CH3^SCS(:M%W"1'Y+9E/1B
M/X[8F$<R8D$<DM$4G1B@DF"'M2,6(R)"S7 HK#B4BH*M;2G2H/;VX*!,WN:(
M.1M428%B(:?!RI&\)GML1"2-0\CW8T'&T58"H;PH:\H2A=K)NPC>%,Z$P;PR
M4HD=(@530Q9%RKY')\.:[_LWHZQUF4DE*E& (&QX_CSD (UAY:"Y3YM:;"(=
ML,Y"*"<\6;7[8,VX-R597!?&3H,TK^_RU6J,0!@Q#F,>+@P&UFI)+B;"MK <
M3DH+*(\POA>;!^K5Y,!:B SRV@]3[5>8$PLZ%,+S=#F#T(\"\(';HS@('&,O
M6[^C.B%AN)W?;7:X6!AFIS<=FT5[_OJI;1YWN2TVW-T/A)=BZY!.MW&-#*OA
M/[=DU9,C -8]TC A2T4WI0V=$H;7S7V<:)5W*5AFXX46<BS47(#K^M6B=W\*
MK0[D[O7.BH7U:PH!HYR$*\;X@6+K28!8/&"#!XTM/Y!+S%N3M:P7MP>1>0=D
M0(3G8D;-N(((H0LG$ESJ/!@*T$\#;1DC;!DB)A!B8)?+%0HF+=$$Z4*_^!JC
M40)WO8ID0)@R3S0!3%%901>$!Q $^$EX"A$H; (_2K4#@CF":.^QU J(>8ES
M<> ;QUH4(A,$B09DY YKS=,&+A#;NP%CO*A PB@%C2WXCY1DKC)+V%+L,6,E
M Y?@),TK8\E$+HB*"T!XO%@GNEVGG#Z&JD_. (LH#BG[:<O@+B+CA-$V4;,S
M$<FE_&*!?!)S)W,3P:$?JR2I,8K+0.C@1$N!*V?$UIY=.[J'!,_\.$QB43,L
M9VXE&5UA(F:*.AW!ZHE("\F1OB)<8:YB8(6)0Q[C7^0K2ZI%NL?VK9ABBX!L
M[$JE,OM!%S^4N%BZSC#)WB-3TVELR:AEVXJ%);5O(9]<JS3F[=B("')_)8J*
M!^2/S,C(NP#V<(OLA#]8"& Q?0&T!W'+4BAR ^XMD/<1/M_(@L U"+'_:RPC
M2:&1P&J68%)+D]MRFK\(7(D'R IQ/)_!II[61DM,:A,6K%D$1:X($67Y,.[1
MM@3A5'*YTZK2*)4OP?\O1X,'!]\Z&JQO'PT>'[W(:# =Z2'1MD>C_N"F^VG(
MVB/6:]^9J>^/3P%3O=>,V.D/1_T;]A]VT[UCG_J##_AZVQY<#?%YUQY>PL/F
M_?M^K_OILM^^V#OK7V\=Z=#7\ZN/6$\&Z=IFM!R8#GKUB@EWXX;14LZP8P$4
M@V&=.5]$U/'N!\3O$DZX^C=\<%!*Z>I!?^/56_UG+1P3A<^Z-Z/NX']NU-]Z
MK%_<N,Q/S7RS!'[F^=$MO,OJC^GU/-#;0667E!&F-AM_II(E21449E,_K>!I
MQ<!P6A9$0E>!:)4H,4DD(ZG0@NI\G\*X+A5S1;_.^V,JLFV:1Z;)#%*,%\7"
MMM($6<\SC:VMGP,./*'*#]43MU"\V;K'SUHVB.::I(Q\;\NLI-Q2^J8%&&R!
M?**;8>$&ID5*RJ_M=?'C=6XYK_!<(K&/!4T4I.TD+;I=9I/8P9-6!L2*!<_W
M4 XA"?*Q(WY]$AY1Z9PZ3>K<.UZM,WV/I-\^:=&MWF:?MVR>441C?=V@J+%7
M+$K97G_"9+IRT6, /U*595NLQPRF:M)-!Q4)8:ZL>7G3F9XVJ<2H+O8= =-1
MR.I1P1C%RT2J7:6X+J/-14OK06Z:9:I6E6,JT)!(:K^ 4KYU1G_D "L11-3E
MW\MH)?Y79C'4IN=$IP&2YROR>QQ1B'Z-?46?*U$0XA'.#HT8I!1Y+9'7]&)E
MD DU.96C3XI_.V'=D2]6[%#.N&5\J,OB,)<%',NZ%((?-(C8.P^I8M<A&\%X
M+Q,:Q4(^-I: "T^$IH,2#[@1%#,TNHH5M3MA["2=!2 X=KA!,7K^'-MH@%#[
MVL)*G*M;R0@[O:1%SOR]VG02F&)-1I;#I6OL.T9&-[%'L6,C7@1;^+%N4? ^
M&7<1U'J+E.HR+T2P==)AZBH]I!02X>9",?04XEXX?F N*T@D6PQ-O4+=8J37
M9(C^ _KKAM4,.%WZ;W[&31=-[+.I099>-G/0"U]_,WPH%J(9-[ OJ:!"<T,I
M94?" @#0M,L0N VE9\F O/\9)E99QEC. US=A^H!84],$0G]U!B)?]HN6G(+
MK5*'AZP=13[B965JVHDCJ=L_ZIF&"9BG*>W.#[^0;R]"/PZV,'GOQYZ=P!7-
MBQ%!T<QH=W)8+.1I+W!WW]2.V!_U:NWMRPS"DJM/T;T@8)A(AY3+ Y.9QN 6
MFM^29--FW71G-CLSUQ7Y2_\W^^IL^=%AT9O*A_+J>-G '1\36FW6FJ:VR4^E
MX'J-C8+B!D'A_VUIXB?CWO00%HSV$#DI>K:/Z):C_IG@-IDJ&7*:*+A.QCK)
M<!/E>+$PE7HJI/-68FX]XK%]G4YTEB8XMUVR+M6#>$GY+!&$)E=3WXQ%THPW
MGP'?,^=I<$O* 2-@$K3&<"?;TQLS"7<'EF;9-QOD:T$U^2<=%^AF:O672]\]
M03A\S@'"8Q.#G_TMT=N7^RT1@S5@VAMJB%L?:2:F0FHY" :B\E*F57ERA'-T
M+[M7%Y<C:'F\2G87E5^DE1X^,)H^L.;PNMWKM1 ]S7WS]8<U7/'C5LWK+Z%Y
MJ[-H_/VDY^=_Z:5_W3-&EA;A<NF!JGBH\:JJ_WQG'MJ/]@F@+0F(VF-MZ@L5
MMU=_)_#+S/@3-FRS6QXJM,K;!EUFRK5CW-7<I]^>8E'_8O6_4$L#!!0    (
M !*GXEP;T?"=:0,  )$,   1    96YT82TR,#(V,#<P,BYX<V2]5FUOVS80
M_EZ@_^&F3QLPB9;=)HL0I^B6!@B09H6;#OM6T-+9(4:1&DDE\;_?D9)L^75.
M,LQ?3/+NN7ONA4>=?W@J)3R@L4*K<90F@PA0Y;H0:CZ.:AMSFPL1?;AX^^;\
MASB&RZOK6XCAWKG*9HP]/CXFQ4PHJV7MR()-<ETRB.-._[>[;_!'8SV#"4KD
M%F%X,CB!7VLABVPXH,TH/4U&?9!![JU!P1UF<,J&S.M!FF;#T^S=+_#E,WSB
MUJ%1<"=*[$-UM3!B?N_@Q_PG"*A+K11*B0NX$HJK7' )7SN^/\.URA/X*"5,
M/,P228OF 8NDM?IDB\SF]UCRMV\ *%O*9HI,UN4X\FEHL_ T-3+19LX*9YA;
M5,A(*28M-"*/>M!_QVUAJ Q>8I? &;?3 .HD/C_O>PA4CJ^Y08K<\5"=D/+3
MP;"G7J!8:@="%O-DKA\8"39->[G8'<)P,!@Q:@9'6<8>1 KUUP&$%T^I+_I.
MMB"/HP!(S\[.6)!N4"K<>@2M]?>L$?:TK7';B:3#S4"MJ\SNK'C)2IL[9\2T
M=GBE37F),UY+<E"KOVLNQ4Q@$;2H]4NJRIK.NH;C9H[NEI=H*Y[C,\I'+;HK
M5Q1^RO[\?/,U=&]TX0$ H:%%66GCH.GK&YV'ZW:@1'X7=Y6-_5&<#N-1FI"Q
M"-1.SGO: MBKB70-\R(BRVX[FHC==RO\(O:+?=YWWZ479V!S1/CXSWS\Z<E1
M\6^-F/^ B5:WKR73FY,OKXGB(F_&8+,\OBXKY*MZLYLT/@^''6^.IN<'O36V
M&$IG_>Y@V-O3[N7Y7L[ L#H^VZO9V?H.GKE2V@5W?3Z\JH2:Z?:(#OW=S;H+
M/,$9A)<@XR8W6N+A]X)51E=HG*#7<C4#&@/W!F?CR#^:<3=>OTL^36B\=BI;
M#M:GBA<S@J"\6='KL$XX#[[Q8O!R^NS@<FG:WX)Q9"G[LC>5_N=P*X//#9<@
MUAOQ9=L?]9>>UK.#]W[N2 /\XMOD>M^CN'P5F>-/6NERT5"\U'GMG]WN_Z,J
M/BDBMKBFOC)E(!6!H.=S0NK?CU)?4NQ(%DA?P"(T;SKP/_I [BSTEUP5T)B#
MGKUSMFEDTWYML?A=781USF5>RV7*6W"K<0BX6:SCD2MF^W'M:5>N[A*SS5O<
MGO1O>W/4S!S:_@-02P,$%     @ $J?B7,DAROE@!@  O$,  !4   !E;G1A
M+3(P,C8P-S R7VQA8BYX;6S-G&UOVS80Q]\/Z'>X>6\VH++C9&M7HVF1.<D0
M+&V"QMV&#4,A2XQ-3.89I)S8WWZD'AHYIF0I/$UYT506[_YW)_^.H9[R]OUZ
M$<$=DXJC..X-^P<]8"+ D(O9<6^E/%\%G/= Q;X(_0@%.^YMF.J]?_?BF[??
M>AZ<GE]\! _F<;Q4H\'@_OZ^']YRH3!:Q5I2]0-<#,#S<OOQY#/\GH8;P2<6
M,5\Q.'QU\ I^6?$H'!T>Z ]'P]?]HZ*39+Y1@]"/V0A>#PX'Q@Z&P]'AZ]&/
M/\/U!SCS5<RD@ E?L*(K+C>2S^8Q?!_\ (G7*0K!HHAMX)P+7P3<C^ FS_<E
M7(B@#R=1!)^,F]))*B;O6-C/5",N_AV9'U.3.KSX!D ?0Z&2?<<]<R2R [&>
MRJB/<J:3/3@:Y"Z]!X_UCLO]4>(P?//FS2 9+5HK;K/5XL/!GQ\N;X(Y6_B>
M/O;ZNPJR,(J/5++_$H/D$-9($$HMS"<O-_/,+F]XZ!T-^VL5]MZ9@-G1\:<L
MNM1;D-0PDABQBL!F.(G>R^SCS5+;LW7,1,@RY:_:&&16<\EN4U5#7B*I6-"?
MX=T@9-P0\I/9\,R&R? [_>'+&#7L)U,52S^(M^-%YA"AS'<F11SW+$Z#[82,
MW8D,MK1\&>0Z>G-/_9G%($#]O2UC+U',W6\E+JQ99.'0,O@EFD;6- U)>LOT
M-A/>YYM]M:9"Q<(D4[B2&J\F7VU2S[M$&?[.M?]Y.WB(_5Q2U5.(8I=-\W5#
M\DS$/-Y\8C-N HGXH[]@=<FT^W8$:&4A6&[C@FNY'A&U:0!XB  FA#.[[>5=
M1+AI\FX@GRST?*W_Q>>1/ZM+\".GCM"UIXZ601=8+4)$E'Y5!B/M3&<+B1:Q
MK)LMQ;PZUF&D'UWHE<3Z-[9I-K'N.'<ZLY:5@A5&[G.K59!V<LU"0!(#=!"B
MZ;65U"WS:X/\W9 ^Q6!E^F:BLZ]+\K9/1P!;$\?=,1=<=W6(*,V%P2@[HTF?
M9I'(FKG28'C-),?P3(2G^KR\*8^/G#L&TUX*5AA1H&H1I&8V#0$Z!I@@9/BV
MD+J5X]KY4RP6+D2 <HDRN51R$^MX8USIN7TSQK#A.=D>J4X7$O7*Q-HN[HN,
M&O*T2XZM@)!$A"PDF)A$*Y#_H2[+>N3IQ5$TT3F/V,?58LIDLXXI^G7:'I8"
MT#[N#OYC+5K*C3JD\D1 4^=KH;=6TA2@3OSU1:A_Q_!;GEX<?PJUI2*=(KRO
M-*QA[ YWI3 MZ3H4;,>BY;[54BQ-\(1Z*%KB) QU 2K[[Y(+-FS6#E:!3ENA
MJB3<8^C> J6BM/AG^B_S#3"1X$I0K6-:*\."_A-J(41_K#>OY 3OQ9/ +[H_
M!^PMY=B@?S C0_ZQ9$O FS" $DP@6MBI"ZA"O5X5A)@G)P57\EKB'1=!PW/;
M,HWG 'Q983;J']F2H6_5;8G_].Q.HY-'HVV"5DJIZH0&]1"VPS6JV(_^XLOF
M%WKL"L^A%>Q%V1IARY*L#2RJ+35!&@ET*,J+-^V54=4 M6MQ?!#*%"B9WP3X
M;9^N'H.R)8Z[8TX/0>WH$(&;_)XWRC2<TN>Y]0!4S63=0#1/)D;7<Q0-+QKN
M^G4$9&D!:!]W =.N101G(@Z).M7%DW;R+4+:)&DW4/^0/(Z9&.-BL1+911E5
ME]82YXZ0K2X%*XQ<X*T0)"(XBP#;(9PI;C'Q(LI-LW?#^08C'O"8B]D'O>*6
MW(_JLFSS[ CDBB*PS,(%X3(U(GX?Y"'7=X:WK92+Y#;*VPW;:\E,?S"-1?(4
MC7E%0%[=WM9?.%0I=(1QC:)PGZ4+UOM4B?#68: 8!]) D$1R!KWM(HK /[$2
M4O0OE%HQZ=X %IWGT0;E!=J;8<>>L"5*M-MJC#1<J_W14D657=*H+,?E#0M6
M>CVU&1Y.)SR.:E_CV/7K:FE35@#:QYV6-58MJD5-)@Y:'1)Y]S5-*_ENK6@:
M).T&ZD3ZYFW;F\UBBK67X(^<.D+4GCI:!EW@M @1D9DI0RKM3&4+B1:1K)LM
MS;QYM@[FNEK6Y&U$NV_'\Z>U$"RWH9A'=_6HY](\ LW;B.WE;9U3:R9/<7_O
M;,'D3'?-KQ+OX[E>C"Q]T? EL!*)3N_P59>%>TW=[_%5R!*QGMT8RP-!&@FR
M4$3W^%HLPW*3KVXMQ1V7>LO\W8EL%T__^H+>\Q]02P,$%     @ $J?B7&A0
MA;NU!   =BH  !4   !E;G1A+3(P,C8P-S R7W!R92YX;6S5FEN/XC84Q]]7
MVN_@IB^MM"%<YK*#AEE19F:%.A<$;%OU9662 UAU;&2; ;[]'@=<$0A3F&ZK
MF <NCO_'?Y^?XS@FUY^6*2<OH#23HA74*M6 @(AEPL2D%<QU2'7,6$"TH2*A
M7 IH!2O0P:>;]^^N?PA#<GO??2(AF1HST\TH6BP6E63,A)9\;C"DKL0RC4@8
MNOJ=X1?RV[JY)ND#!ZJ!U"^J%^27.>-)LU[%'XW:9:6Q+5) ;3224 --<AG5
M(UN/U&K-^F7S["/I/9([J@TH088LA6VIG*T4FTP-^2G^F62J6RD$< XK<L\$
M%3&CG R<WP^D*^(*:7-.^E:FT:0&]0))91.5,_%7T[Z-K'7R_AW!%V91Z*RT
M%=A<;%*Q'"E>D6J"=JN-R(F";<UR3[1H9)+:U=55E!W-U]>LJ#8V4(O^>'P8
MQ%-(:8@$D%B\TQ2Z2<S?ZFUSY]'ZH*NO65-GD1YDG*7^B&Z1@S7LK]!5"VU1
M6*N'C5IEJ9/@QC:YSJJ2'/HP)O;S2[^;:Q,0E:'9<,K@5R^K]<C0I10R7456
M$=W*>)Z",.ZS+9([89A9=<58JC3K1T"RE#:G"L:M "O1T$6S;G[L8Z"OIP0R
MJQF>$YJE,PX!B;9Z,U,X<K !6_L!"W("6!H0"20NC.W ?]+?FS71S;"5<:[_
M[K3-<&F(*Q/Y$B7 ;(OG]HM-SGF6&/SQM2-QIFB/M%$T-OD$<#M.I'*%G(Z
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M-#$R9&5X,3$N:'1M4$L! A0#%     @ $J?B7*/-H\"]"P  N"H  !
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7;%!+!08     !@ & 'T!  !IS0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d123412d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="enta-20260702.xsd" xlink:type="simple"/>
    <context id="duration_2026-07-02_to_2026-07-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001177648</identifier>
        </entity>
        <period>
            <startDate>2026-07-02</startDate>
            <endDate>2026-07-02</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2026-07-02_to_2026-07-02"
      id="Hidden_dei_EntityRegistrantName">ENANTA PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-277">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-07-02_to_2026-07-02"
      id="Hidden_dei_EntityCentralIndexKey">0001177648</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-288">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-289">2026-07-02</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-290">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-291">001-35839</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-292">04-3205099</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-293">4 Kingsbury Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-294">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-295">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-296">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-297">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-298">607-0800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-299">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-300">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-301">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-302">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-303">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-304">ENTA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-305">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-07-02_to_2026-07-02" id="ixv-306">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
